104 results on '"D. Eefting"'
Search Results
2. Complications Following Percutaneous Mitral Valve Repair
- Author
-
Livia Gheorghe, Alfonso Ielasi, Benno J. W. M. Rensing, Frank D. Eefting, Leo Timmers, Azeem Latib, and Martin J. Swaans
- Subjects
mitral valve (MV) repair ,complications ,transcatheter interventions ,MitraClip® ,Carillon device ,Mitralign ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Mitral valve disease affects more than 4 million people in the United States and it is the second most prevalent valvulopathy in Europe. The gold standard of treatment in these patients is surgical repair or mitral valve replacement. In the last decade, numerous transcatheter therapies have been developed to overcome the increased number of subjects with symptomatic severe mitral regurgitation and high surgical risk. The Mitraclip (Abbott Vascular, Menlo Park, CA), PASCAL (Edwards Lifesciences, Irvine, CA, USA), the Carillon™ Mitral Contour System™ (Cardiac Dimension Inc., Kirkland, WA, USA), the Mitralign™ (Mitralign, Tewksbury, Massachusetts), and the Cardioband (Edwards Lifesciences, Irvine, CA) are the principal percutaneous devices for mitral valve repair. We present an evidence-based clinical update that provides an overview of these technologies and their potential complications.
- Published
- 2019
- Full Text
- View/download PDF
3. Transcatheter tricuspid valve repair: early experience in the Netherlands
- Author
-
M. Holierook, Leo Timmers, B.J. Bouma, Benno J. Rensing, Karel T. Koch, Frank D. Eefting, M. J. Swaans, R. J. de Winter, J. Baan, Frank Meijerink, Cardiology, Graduate School, ACS - Heart failure & arrhythmias, ACS - Pulmonary hypertension & thrombosis, ACS - Atherosclerosis & ischemic syndromes, and APH - Aging & Later Life
- Subjects
medicine.medical_specialty ,Tricuspid valve ,New York Heart Association Class ,business.industry ,MitraClip ,valvular heart disease ,Renal function ,Atrial fibrillation ,Regurgitation (circulation) ,Tricuspid regurgitation ,medicine.disease ,Valvular heart disease ,Surgery ,medicine.anatomical_structure ,Quality of life ,Echocardiography ,medicine ,Original Article ,Cardiology and Cardiovascular Medicine ,business ,Transcatheter treatment - Abstract
Background Symptomatic tricuspid regurgitation (TR) is increasingly prevalent and impairs quality of life and survival, despite medical treatment. Transcatheter tricuspid valve repair (TTVR) has recently become available as a treatment option for patients not eligible for tricuspid valve surgery. In this study we describe the early experience with TTVR in the Netherlands. Methods All consecutive patients scheduled for TTVR in two tertiary hospitals were included in the current study. Patients were symptomatic and had severe functional TR. TTVR was performed either with the MitraClip (off-label use) or dedicated TriClip delivery system and device. Procedural success was defined as achievement of clip implantation, TR reduction ≥ 1 grade and no need for re-do surgical or transcatheter intervention. Clinical improvement was evaluated after 4 weeks. Results Twenty-one patients (median age 78 years, 33% male, 95% New York Heart Association class ≥ 3, 100% history of atrial fibrillation) underwent TTVR. Procedural success was achieved in 16 patients, of whom 15 reported symptomatic improvement (New York Heart Association class 1 or 2). There was no in-hospital mortality and no major complications occurred. Baseline glomerular filtration rate and TR coaptation gap size were associated with procedural success. Conclusion The current study showed that TTVR seems a promising treatment option for patients with severe functional TR deemed high risk for surgery. Successful TR reduction is most likely in patients with limited coaptation gap size and strongly determines clinical benefit. Adequate patient selection and timing of treatment seem essential for an optimal patient outcome.
- Published
- 2021
4. Editor's Choice – Nationwide Analysis of Patients Undergoing Iliac Artery Aneurysm Repair in the Netherlands
- Author
-
Hamid Jalalzadeh, Reza Indrakusuma, Mark J.W. Koelemay, Ron Balm, L.H. Van den Akker, P.J. Van den Akker, G.J. Akkersdijk, G.P. Akkersdijk, W.L. Akkersdijk, M.G. van Andringa de Kempenaer, C.H. Arts, J.A. Avontuur, J.G. Baal, O.J. Bakker, R. Balm, W.B. Barendregt, M.H. Bender, B.L. Bendermacher, M. van den Berg, P. Berger, R.J. Beuk, J.D. Blankensteijn, R.J. Bleker, J.H. Bockel, M.E. Bodegom, K.E. Bogt, A.P. Boll, M.H. Booster, B.L. Borger van der Burg, G.J. de Borst, W.T. Bos-van Rossum, J. Bosma, J.M. Botman, L.H. Bouwman, J.C. Breek, V. Brehm, M.J. Brinckman, T.H. van den Broek, H.L. Brom, M.T. de Bruijn, J.L. de Bruin, P. Brummel, J.P. van Brussel, S.E. Buijk, M.G. Buimer, D.H. Burger, H.C. Buscher, G. den Butter, E. Cancrinus, P.H. Castenmiller, G. Cazander, H.M. Coveliers, P.H. Cuypers, J.H. Daemen, I. Dawson, A.F. Derom, A.R. Dijkema, J. Diks, M.K. Dinkelman, M. Dirven, D.E. Dolmans, R.C. van Doorn, L.M. van Dortmont, M.M. van der Eb, D. Eefting, G.J. van Eijck, J.W. Elshof, B.H. Elsman, A. van der Elst, M.I. van Engeland, R.G. van Eps, M.J. Faber, W.M. de Fijter, B. Fioole, W.M. Fritschy, R.H. Geelkerken, W.B. van Gent, G.J. Glade, B. Govaert, R.P. Groenendijk, H.G. de Groot, R.F. van den Haak, E.F. de Haan, G.F. Hajer, J.F. Hamming, E.S. van Hattum, C.E. Hazenberg, P.P. Hedeman Joosten, J.N. Helleman, L.G. van der Hem, J.M. Hendriks, J.A. van Herwaarden, J.M. Heyligers, J.W. Hinnen, R.J. Hissink, G.H. Ho, P.T. den Hoed, M.T. Hoedt, F. van Hoek, R. Hoencamp, W.H. Hoffmann, A.W. Hoksbergen, E.J. Hollander, L.C. Huisman, R.G. Hulsebos, K.M. Huntjens, M.M. Idu, M.J. Jacobs, M.F. van der Jagt, J.R. Jansbeken, R.J. Janssen, H.H. Jiang, S.C. de Jong, V. Jongkind, M.R. Kapma, B.P. Keller, A. Khodadade Jahrome, J.K. Kievit, P.L. Klemm, P. Klinkert, B. Knippenberg, N.A. Koedam, M.J. Koelemay, J.L. Kolkert, G.G. Koning, O.H. Koning, A.G. Krasznai, R.M. Krol, R.H. Kropman, R.R. Kruse, L. van der Laan, M.J. van der Laan, J.H. van Laanen, J.H. Lardenoye, J.A. Lawson, D.A. Legemate, V.J. Leijdekkers, M.S. Lemson, M.M. Lensvelt, M.A. Lijkwan, R.C. Lind, F.T. van der Linden, P.F. Liqui Lung, M.J. Loos, M.C. Loubert, D.E. Mahmoud, C.G. Manshanden, E.C. Mattens, R. Meerwaldt, B.M. Mees, R. Metz, R.C. Minnee, J.C. de Mol van Otterloo, F.L. Moll, Y.C. Montauban van Swijndregt, M.J. Morak, R.H. van de Mortel, W. Mulder, S.K. Nagesser, C.C. Naves, J.H. Nederhoed, A.M. Nevenzel-Putters, A.J. de Nie, D.H. Nieuwenhuis, J. Nieuwenhuizen, R.C. van Nieuwenhuizen, D. Nio, A.P. Oomen, B.I. Oranen, J. Oskam, H.W. Palamba, A.G. Peppelenbosch, A.S. van Petersen, T.F. Peterson, B.J. Petri, M.E. Pierie, A.J. Ploeg, R.A. Pol, E.D. Ponfoort, P.P. Poyck, A. Prent, S. ten Raa, J.T. Raymakers, M. Reichart, B.L. Reichmann, M.M. Reijnen, A. Rijbroek, M.J. van Rijn, R.A. de Roo, E.V. Rouwet, C.G. Rupert, B.R. Saleem, M.R. van Sambeek, M.G. Samyn, H.P. van ’t Sant, J. van Schaik, P.M. van Schaik, D.M. Scharn, M.R. Scheltinga, A. Schepers, P.M. Schlejen, F.J. Schlosser, F.P. Schol, O. Schouten, M.H. Schreinemacher, M.A. Schreve, G.W. Schurink, C.J. Sikkink, M.P. Siroen, A. te Slaa, H.J. Smeets, L. Smeets, A.A. de Smet, P. de Smit, P.C. Smit, T.M. Smits, M.G. Snoeijs, A.O. Sondakh, T.J. van der Steenhoven, S.M. van Sterkenburg, D.A. Stigter, H. Stigter, R.P. Strating, G.N. Stultiëns, J.E. Sybrandy, J.A. Teijink, B.J. Telgenkamp, M.J. Testroote, R.M. The, W.J. Thijsse, I.F. Tielliu, R.B. van Tongeren, R.J. Toorop, J.H. Tordoir, E. Tournoij, M. Truijers, K. Türkcan, R.P. Tutein Nolthenius, Ç. Ünlü, A.A. Vafi, A.C. Vahl, E.J. Veen, H.T. Veger, M.G. Veldman, H.J. Verhagen, B.A. Verhoeven, C.F. Vermeulen, E.G. Vermeulen, B.P. Vierhout, M.J. Visser, J.A. van der Vliet, C.J. Vlijmen - van Keulen, H.G. Voesten, R. Voorhoeve, A.W. Vos, B. de Vos, G.A. Vos, B.H. Vriens, P.W. Vriens, A.C. de Vries, J.P. de Vries, M. de Vries, C. van der Waal, E.J. Waasdorp, B.M. Wallis de Vries, L.A. van Walraven, J.L. van Wanroij, M.C. Warlé, V. van Weel, A.M. van Well, G.M. Welten, R.J. Welten, J.J. Wever, A.M. Wiersema, O.R. Wikkeling, W.I. Willaert, J. Wille, M.C. Willems, E.M. Willigendael, W. Wisselink, M.E. Witte, C.H. Wittens, I.C. Wolf-de Jonge, O. Yazar, C.J. Zeebregts, M.L. van Zeeland, Surgery, ACS - Atherosclerosis & ischemic syndromes, Pathology, VU University medical center, Pediatrics, Dermatology, ACS - Microcirculation, ACS - Diabetes & metabolism, Graduate School, 02 Surgical specialisms, Robotics and image-guided minimally-invasive surgery (ROBOTICS), Neurology, Erasmus MC other, Molecular Genetics, Erasmus School of Economics, Socio-Medical Sciences (SMS), Cell biology, Gynecological Oncology, Research & Education, Child and Adolescent Psychiatry / Psychology, Cardiology, Urology, Erasmus School of Health Policy & Management, Erasmus School of Social and Behavioural Sciences, Erasmus School of Law, Department of History, Department of Psychology, Education and Child Studies, Obstetrics & Gynecology, Department of Finance, General Practice, Applied Economics, Pediatric Surgery, Department of Business-Society Management, Commercial Law and Financial Law, Radiology & Nuclear Medicine, Business Economics, Neurosurgery, Public Health, Anesthesiology, Internal Medicine, Hematology, Intensive Care, Psychiatry, WP ESPhil, and Gastroenterology & Hepatology
- Subjects
Male ,medicine.medical_specialty ,medicine.medical_treatment ,Iliac Aneurysm/epidemiology ,Patient characteristics ,Netherlands/epidemiology ,030204 cardiovascular system & hematology ,030230 surgery ,Iliac Artery/pathology ,Endovascular aneurysm repair ,Iliac Artery ,03 medical and health sciences ,0302 clinical medicine ,Aneurysm ,Sex Factors ,medicine ,80 and over ,Humans ,EVAR ,Registries ,Iliac artery aneurysm ,Aged ,Netherlands ,Retrospective Studies ,Surgical repair ,Aged, 80 and over ,business.industry ,Open repair ,Endovascular Procedures ,Retrospective cohort study ,Guideline ,Vascular surgery ,medicine.disease ,Guideline Adherence/statistics & numerical data ,Surgery ,Endovascular Procedures/methods ,Aneurysm repair ,Treatment Outcome ,Iliac Aneurysm ,Female ,Guideline Adherence ,Cardiology and Cardiovascular Medicine ,business - Abstract
OBJECTIVE: The new 2019 guideline of the European Society for Vascular Surgery (ESVS) recommends consideration for elective iliac artery aneurysm (eIAA) repair when the iliac diameter exceeds 3.5 cm, as opposed to 3.0 cm previously. The current study assessed diameters at time of eIAA repair and ruptured IAA (rIAA) repair and compared clinical outcomes after open surgical repair (OSR) and endovascular aneurysm repair (EVAR).METHODS: This retrospective observational study used the nationwide Dutch Surgical Aneurysm Audit (DSAA) registry that includes all patients who undergo aorto-iliac aneurysm repair in the Netherlands. All patients who underwent primary IAA repair between 1 January 2014 and 1 January 2018 were included. Diameters at time of eIAA and rIAA repair were compared in a descriptive fashion. The anatomical location of the IAA was not registered in the registry. Patient characteristics and outcomes of OSR and EVAR were compared with appropriate statistical tests.RESULTS: The DSAA registry comprised 974 patients who underwent IAA repair. A total of 851 patients were included after exclusion of patients undergoing revision surgery and patients with missing essential variables. eIAA repair was carried out in 713 patients, rIAA repair in 102, and symptomatic IAA repair in 36. OSR was performed in 205, EVAR in 618, and hybrid repairs and conversions in 28. The median maximum IAA diameter at the time of eIAA and rIAA repair was 43 (IQR 38-50) mm and 68 (IQR 58-85) mm, respectively. Mortality was 1.3% (95% CI 0.7-2.4) after eIAA repair and 25.5% (95% CI 18.0-34.7) after rIAA repair. Mortality was not significantly different between the OSR and EVAR subgroups. Elective OSR was associated with significantly more complications than EVAR (intra-operative: 9.8% vs. 3.6%, post-operative: 34.0% vs. 13.8%, respectively).CONCLUSION: In the Netherlands, most eIAA repairs are performed at diameters larger than recommended by the ESVS guideline. These findings appear to support the recent increase in the threshold diameter for eIAA repair.
- Published
- 2020
- Full Text
- View/download PDF
5. Nationwide Outcomes of Octogenarians Following Open or Endovascular Management After Ruptured Abdominal Aortic Aneurysms
- Author
-
Alberga, Anna J., primary, de Bruin, Jorg L., additional, Bastos Gonçalves, Frederico, additional, Karthaus, Eleonora G., additional, Wilschut, Janneke A., additional, van Herwaarden, Joost A., additional, Wever, Jan J., additional, Verhagen, Hence J. M., additional, PJ, Van den Akker, additional, GJ, Akkersdijk, additional, GP, Akkersdijk, additional, WL, Akkersdijk, additional, MG, van Andringa de Kempenaer, additional, CH, Arts, additional, JA, Avontuur, additional, OJ, Bakker, additional, R, Balm, additional, WB, Barendregt, additional, JA, Bekken, additional, MH, Bender, additional, BL, Bendermacher, additional, M, van den Berg, additional, P, Berger, additional, RJ, Beuk, additional, JD, Blankensteijn, additional, RJ, Bleker, additional, JJ, Blok, additional, AS, Bode, additional, ME, Bodegom, additional, KE, van der Bogt, additional, AP, Boll, additional, MH, Booster, additional, BL, Borger van der Burg, additional, GJ, de Borst, additional, WT, Bos-van Rossum, additional, J, Bosma, additional, JM, Botman, additional, LH, Bouwman, additional, V, Brehm, additional, MT, de Bruijn, additional, JL, de Bruin, additional, P, Brummel, additional, JP, van Brussel, additional, SE, Buijk, additional, MA, Buijs, additional, MG, Buimer, additional, DH, Burger, additional, HC, Buscher, additional, E, Cancrinus, additional, PH, Castenmiller, additional, G, Cazander, additional, AM, Coester, additional, PH, Cuypers, additional, JH, Daemen, additional, I, Dawson, additional, JE, Dierikx, additional, ML, Dijkstra, additional, J, Diks, additional, MK, Dinkelman, additional, M, Dirven, additional, DE, Dolmans, additional, RC, van Doorn, additional, LM, van Dortmont, additional, JW, Drouven, additional, MM, van der Eb, additional, D, Eefting, additional, GJ, van Eijck, additional, JW, Elshof, additional, BH, Elsman, additional, A, van der Elst, additional, MI, van Engeland, additional, RG, van Eps, additional, MJ, Faber, additional, WM, de Fijter, additional, B, Fioole, additional, TM, Fokkema, additional, FA, Frans, additional, WM, Fritschy, additional, PH, Fung Kon Jin, additional, RH, Geelkerken, additional, WB, van Gent, additional, GJ, Glade, additional, B, Govaert, additional, RP, Groenendijk, additional, HG, de Groot, additional, RF, van den Haak, additional, EF, de Haan, additional, GF, Hajer, additional, JF, Hamming, additional, ES, van Hattum, additional, CE, Hazenberg, additional, PP, Hedeman Joosten, additional, JN, Helleman, additional, LG, van der Hem, additional, JM, Hendriks, additional, JA, van Herwaarden, additional, JM, Heyligers, additional, JW, Hinnen, additional, RJ, Hissink, additional, GH, Ho, additional, PT, den Hoed, additional, MT, Hoedt, additional, F, van Hoek, additional, R, Hoencamp, additional, WH, Hoffmann, additional, W, Hogendoorn, additional, AW, Hoksbergen, additional, EJ, Hollander, additional, M, Hommes, additional, CJ, Hopmans, additional, LC, Huisman, additional, RG, Hulsebos, additional, KM, Huntjens, additional, MM, Idu, additional, MJ, Jacobs, additional, MF, van der Jagt, additional, JR, Jansbeken, additional, RJ, Janssen, additional, HH, Jiang, additional, SC, de Jong, additional, TA, Jongbloed-Winkel, additional, V, Jongkind, additional, MR, Kapma, additional, BP, Keller, additional, A, Khodadade Jahrome, additional, JK, Kievit, additional, PL, Klemm, additional, P, Klinkert, additional, NA, Koedam, additional, MJ, Koelemaij, additional, JL, Kolkert, additional, GG, Koning, additional, OH, Koning, additional, R, Konings, additional, AG, Krasznai, additional, RM, Krol, additional, RH, Kropman, additional, RR, Kruse, additional, L, van der Laan, additional, n MJ, van der Laa, additional, JH, van Laanen, additional, GW, van Lammeren, additional, DA, Lamprou, additional, JH, Lardenoye, additional, GJ, Lauret, additional, BJ, Leenders, additional, DA, Legemate, additional, VJ, Leijdekkers, additional, MS, Lemson, additional, MM, Lensvelt, additional, MA, Lijkwan, additional, RC, Lind, additional, FT, van der Linden, additional, PF, Liqui Lung, additional, MJ, Loos, additional, MC, Loubert, additional, KM, van de Luijtgaarden, additional, DE, Mahmoud, additional, CG, Manshanden, additional, EC, Mattens, additional, R, Meerwaldt, additional, BM, Mees, additional, GC, von Meijenfeldt, additional, TP, Menting, additional, R, Metz, additional, RC, Minnee, additional, JC, de Mol van Otterloo, additional, MJ, Molegraaf, additional, YC, Montauban van Swijndregt, additional, MJ, Morak, additional, RH, van de Mortel, additional, W, Mulder, additional, SK, Nagesser, additional, CC, Naves, additional, JH, Nederhoed, additional, AM, Nevenzel-Putters, additional, AJ, de Nie, additional, DH, Nieuwenhuis, additional, J, Nieuwenhuizen, additional, RC, van Nieuwenhuizen, additional, D, Nio, additional, VJ, Noyez, additional, AP, Oomen, additional, BI, Oranen, additional, J, Oskam, additional, HW, Palamba, additional, AG, Peppelenbosch, additional, AS, van Petersen, additional, BJ, Petri, additional, ME, Pierie, additional, AJ, Ploeg, additional, RA, Pol, additional, ED, Ponfoort, additional, IC, Post, additional, PP, Poyck, additional, A, Prent, additional, S, ten Raa, additional, JT, Raymakers, additional, M, Reichart, additional, BL, Reichmann, additional, MM, Reijnen, additional, JA, de Ridder, additional, A, Rijbroek, additional, MJ, van Rijn, additional, RA, de Roo, additional, EV, Rouwet, additional, BR, Saleem, additional, PB, Salemans, additional, MR, van Sambeek, additional, MG, Samyn, additional, HP, van ‘t Sant, additional, J, van Schaik, additional, PM, van Schaik, additional, DM, Scharn, additional, MR, Scheltinga, additional, A, Schepers, additional, PM, Schlejen, additional, FJ, Schlosser, additional, FP, Schol, additional, VP, Scholtes, additional, O, Schouten, additional, MA, Schreve, additional, GW, Schurink, additional, CJ, Sikkink, additional, Slaa A, te, additional, HJ, Smeets, additional, L, Smeets, additional, RR, Smeets, additional, AA, de Smet, additional, PC, Smit, additional, TM, Smits, additional, MG, Snoeijs, additional, AO, Sondakh, additional, MJ, Speijers, additional, TJ, van der Steenhoven, additional, SM, van Sterkenburg, additional, DA, Stigter, additional, RA, Stokmans, additional, RP, Strating, additional, GN, Stultiëns, additional, JE, Sybrandy, additional, JA, Teijink, additional, BJ, Telgenkamp, additional, M, Teraa, additional, MJ, Testroote, additional, T, Tha-In, additional, RM, The, additional, WJ, Thijsse, additional, I, Thomassen, additional, IF, Tielliu, additional, RB, van Tongeren, additional, RJ, Toorop, additional, E, Tournoij, additional, M, Truijers, additional, K, Türkcan, additional, RP, Tutein Nolthenius, additional, Ç, Ünlü, additional, RH, Vaes, additional, AA, Vafi, additional, AC, Vahl, additional, EJ, Veen, additional, HT, Veger, additional, MG, Veldman, additional, S, Velthuis, additional, HJ, Verhagen, additional, BA, Verhoeven, additional, CF, Vermeulen, additional, EG, Vermeulen, additional, BP, Vierhout, additional, RJ, van der Vijver-Coppen, additional, MJ, Visser, additional, JA, van der Vliet, additional, CJ, Vlijmen—van Keulen, additional, R, Voorhoeve, additional, JR, van der Vorst, additional, AW, Vos, additional, B, de Vos, additional, CG, Vos, additional, GA, Vos, additional, MT, Voute, additional, BH, Vriens, additional, PW, Vriens, additional, AC, de Vries, additional, DK, de Vries, additional, JP, de Vries, additional, M, de Vries, additional, C, van der Waal, additional, EJ, Waasdorp, additional, BM, Wallis de Vries, additional, LA, van Walraven, additional, JL, van Wanroij, additional, MC, Warlé, additional, W, van de Water, additional, V, van Weel, additional, AM, van Well, additional, GM, Welten, additional, RJ, Welten, additional, JJ, Wever, additional, AM, Wiersema, additional, OR, Wikkeling, additional, WI, Willaert, additional, J, Wille, additional, MC, Willems, additional, EM, Willigendael, additional, ED, Wilschut, additional, W, Wisselink, additional, ME, Witte, additional, CH, Wittens, additional, CY, Wong, additional, R, Wouda, additional, O, Yazar, additional, KK, Yeung, additional, CJ, Zeebregts, additional, and ML, van Zeeland, additional
- Published
- 2022
- Full Text
- View/download PDF
6. Toward Optimizing Risk Adjustment in the Dutch Surgical Aneurysm Audit
- Author
-
Niki Lijftogt, Anco Vahl, Esmee M. van der Willik, Vanessa J. Leijdekkers, Michel W.J.M. Wouters, Jaap F. Hamming, L.H. Van den Akker, P.J. Van den Akker, G.J. Akkersdijk, G.P. Akkersdijk, W.L. Akkersdijk, M.G. van Andringa de Kempenaer, C.H. Arts, J.A. Avontuur, J.G. Baal, O.J. Bakker, R. Balm, W.B. Barendregt, M.H. Bender, B.L. Bendermacher, M. van den Berg, P. Berger, R.J. Beuk, J.D. Blankensteijn, R.J. Bleker, J.H. Bockel, M.E. Bodegom, K.E. Bogt, A.P. Boll, M.H. Booster, B.L. Borger van der Burg, G.J. de Borst, W.T. Bos-van Rossum, J. Bosma, J.M. Botman, L.H. Bouwman, J.C. Breek, V. Brehm, M.J. Brinckman, T.H. van den Broek, H.L. Brom, M.T. de Bruijn, J.L. de Bruin, P. Brummel, J.P. van Brussel, S.E. Buijk, M.G. Buimer, D.H. Burger, H.C. Buscher, G. den Butter, E. Cancrinus, P.H. Castenmiller, G. Cazander, H.M. Coveliers, P.H. Cuypers, J.H. Daemen, I. Dawson, A.F. Derom, A.R. Dijkema, J. Diks, M.K. Dinkelman, M. Dirven, D.E. Dolmans, R.C. van Doorn, L.M. van Dortmont, M.M. van der Eb, D. Eefting, G.J. van Eijck, J.W. Elshof, B.H. Elsman, A. van der Elst, M.I. van Engeland, R.G. van Eps, M.J. Faber, W.M. de Fijter, B. Fioole, W.M. Fritschy, R.H. Geelkerken, W.B. van Gent, G.J. Glade, B. Govaert, R.P. Groenendijk, H.G. de Groot, R.F. van den Haak, E.F. de Haan, G.F. Hajer, J.F. Hamming, E.S. van Hattum, C.E. Hazenberg, P.P. Hedeman Joosten, J.N. Helleman, L.G. van der Hem, J.M. Hendriks, J.A. van Herwaarden, J.M. Heyligers, J.W. Hinnen, R.J. Hissink, Ho GH, P.T. den Hoed, M.T. Hoedt, F. van Hoek, R. Hoencamp, W.H. Hoffmann, A.W. Hoksbergen, E.J. Hollander, L.C. Huisman, R.G. Hulsebos, K.M. Huntjens, M.M. Idu, M.J. Jacobs, M.F. van der Jagt, J.R. Jansbeken, R.J. Janssen, H.H. Jiang, S.C. de Jong, V. Jongkind, M.R. Kapma, B.P. Keller, A. Khodadade Jahrome, J.K. Kievit, P.L. Klemm, P. Klinkert, B. Knippenberg, N.A. Koedam, M.J. Koelemaij, J.L. Kolkert, G.G. Koning, O.H. Koning, A.G. Krasznai, R.M. Krol, R.H. Kropman, R.R. Kruse, L. van der Laan, M.J. van der Laan, J.H. van Laanen, J.H. Lardenoye, J.A. Lawson, D.A. Legemate, V.J. Leijdekkers, M.S. Lemson, M.M. Lensvelt, M.A. Lijkwan, R.C. Lind, F.T. van der Linden, P.F. Liqui Lung, M.J. Loos, M.C. Loubert, D.E. Mahmoud, C.G. Manshanden, E.C. Mattens, R. Meerwaldt, B.M. Mees, R. Metz, R.C. Minnee, J.C. de Mol van Otterloo, F.L. Moll, Y.C. Montauban van Swijndregt, M.J. Morak, R.H. van de Mortel, W. Mulder, S.K. Nagesser, C.C. Naves, J.H. Nederhoed, A.M. Nevenzel-Putters, A.J. de Nie, D.H. Nieuwenhuis, J. Nieuwenhuizen, R.C. van Nieuwenhuizen, D. Nio, A.P. Oomen, B.I. Oranen, J. Oskam, H.W. Palamba, A.G. Peppelenbosch, A.S. van Petersen, T.F. Peterson, B.J. Petri, M.E. Pierie, A.J. Ploeg, R.A. Pol, E.D. Ponfoort, P.P. Poyck, A. Prent, S. ten Raa, J.T. Raymakers, M. Reichart, B.L. Reichmann, M.M. Reijnen, A. Rijbroek, M.J. van Rijn, R.A. de Roo, E.V. Rouwet, C.G. Rupert, B.R. Saleem, M.R. van Sambeek, M.G. Samyn, H.P. van 't Sant, J. van Schaik, P.M. van Schaik, D.M. Scharn, M.R. Scheltinga, A. Schepers, P.M. Schlejen, F.J. Schlosser, F.P. Schol, O. Schouten, M.H. Schreinemacher, M.A. Schreve, G.W. Schurink, C.J. Sikkink, M.P. Siroen, A. te Slaa, H.J. Smeets, L. Smeets, A.A. de Smet, P. de Smit, P.C. Smit, T.M. Smits, M.G. Snoeijs, A.O. Sondakh, T.J. van der Steenhoven, S.M. van Sterkenburg, D.A. Stigter, H. Stigter, R.P. Strating, G.N. Stultiëns, J.E. Sybrandy, J.A. Teijink, B.J. Telgenkamp, M.J. Testroote, R.M. The, W.J. Thijsse, I.F. Tielliu, R.B. van Tongeren, R.J. Toorop, J.H. Tordoir, E. Tournoij, M. Truijers, K. Türkcan, R.P. Tutein Nolthenius, Ç. Ünlü, A.A. Vafi, A.C. Vahl, E.J. Veen, H.T. Veger, M.G. Veldman, H.J. Verhagen, B.A. Verhoeven, C.F. Vermeulen, E.G. Vermeulen, B.P. Vierhout, M.J. Visser, J.A. van der Vliet, C.J. Vlijmen - van Keulen, H.G. Voesten, R. Voorhoeve, A.W. Vos, B. de Vos, G.A. Vos, B.H. Vriens, Vriens PW, A.C. de Vries, J.P. de Vries, M. de Vries, C. van der Waal, E.J. Waasdorp, B.M. Wallis de Vries, L.A. van Walraven, J.L. van Wanroij, M.C. Warlé, V. van Weel, A.M. van Well, G.M. Welten, R.J. Welten, J.J. Wever, A.M. Wiersema, O.R. Wikkeling, W.I. Willaert, J. Wille, M.C. Willems, E.M. Willigendael, W. Wisselink, M.E. Witte, C.H. Wittens, I.C. Wolf-de Jonge, O. Yazar, C.J. Zeebregts, M.L. van Zeeland, Surgery, ACS - Atherosclerosis & ischemic syndromes, Multi-Modality Medical Imaging, Gastroenterology and hepatology, Pediatrics, Hematology laboratory, Obstetrics and gynaecology, Amsterdam Movement Sciences - Restoration and Development, Public and occupational health, AGEM - Digestive immunity, Amsterdam Reproduction & Development (AR&D), ACS - Microcirculation, ACS - Diabetes & metabolism, RS: CAPHRI - R5 - Optimising Patient Care, and Epidemiologie
- Subjects
Male ,medicine.medical_specialty ,Time Factors ,SURGERY ,Aortic Rupture ,UT-Hybrid-D ,030204 cardiovascular system & hematology ,Logistic regression ,Risk Assessment ,Decision Support Techniques ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,Predictive Value of Tests ,Risk Factors ,Electronic Health Records ,Humans ,Medicine ,Prospective Studies ,Registries ,Prospective cohort study ,Aged ,Netherlands ,Aged, 80 and over ,ABDOMINAL AORTIC-ANEURYSM ,Medical Audit ,business.industry ,MORTALITY ,Glasgow Coma Scale ,Reproducibility of Results ,General Medicine ,medicine.disease ,Comorbidity ,Abdominal aortic aneurysm ,n/a OA procedure ,ERA ,MODEL ,Treatment Outcome ,Predictive value of tests ,Emergency medicine ,Female ,Cardiology and Cardiovascular Medicine ,business ,Risk assessment ,Vascular Surgical Procedures ,Aortic Aneurysm, Abdominal ,Abdominal surgery - Abstract
Background: To compare hospital outcomes of aortic aneurysm surgery, casemix correction for preoperative variables is essential. Most of these variables can be deduced from mortality risk prediction models. Our aim was to identify the optimal set of preoperative variables associated with mortality to establish a relevant and efficient casemix model.Methods: All patients prospectively registered between 2013 and 2016 in the Dutch Surgical Aneurysm Audit (DSAA) were included for the analysis. After multiple imputation for missing variables, predictors for mortality following univariable logistic regression were analyzed in a manual backward multivariable logistic regression model and compared with three standard mortality risk prediction models: Glasgow Aneurysm Score (GAS, mainly clinical parameters), Vascular Biochemical and Haematological Outcome Model (VBHOM, mainly laboratory parameters), and Dutch Aneurysm Score (DAS, both clinical and laboratory parameters). Discrimination and calibration were tested and considered good with a C-statistic > 0.8 and Hosmer-Lemeshow (H-L) P > 0.05.Results: There were 12,401 patients: 9,537 (76.9%) elective patients (EAAA), 913 (7.4%) acute symptomatic patients (SAAA), and 1,951 (15.7%) patients with acute rupture (RAAA). Overall postoperative mortality was 6.5%; 1.8% after EAAA surgery, 6.6% after SAAA, and 29.6% after RAAA surgery. The optimal set of independent variables associated with mortality was a mix of clinical and laboratory parameters: gender, age, pulmonary comorbidity, operative setting, creatinine, aneurysm size, hemoglobin, Glasgow coma scale, electrocardiography, and systolic blood pressure (C-statistic 0.871). External validation overall of VBHOM, DAS, and GAS revealed C-statistics of 0.836, 0.782, and 0.761, with an H-L of 0.028, 0.00, and 0.128, respectively.Conclusions: The optimal set of variables for casemix correction in the DSAA comprises both clinical and laboratory parameters, which can be collected easily from electronic patient files and will lead to an efficient casemix model.
- Published
- 2019
- Full Text
- View/download PDF
7. Implementing a minimally invasive approach (combining radial approach, small guiding catheters and minimization of double access) for coronary chronic total occlusion intervention according to the hybrid algorithm: The Minimalistic Hybrid Algorithm
- Author
-
Maarten J. Suttorp, Jan Peter van Kuijk, Jurriën M. ten Berg, Benno J. Rensing, Frank D. Eefting, Pierfrancesco Agostoni, Jan Van der Heyden, and Carlo Zivelonghi
- Subjects
Mathematical optimization ,030204 cardiovascular system & hematology ,Coronary Angiography ,Total occlusion ,03 medical and health sciences ,Percutaneous Coronary Intervention ,0302 clinical medicine ,Operator (computer programming) ,Humans ,Minimally Invasive Surgical Procedures ,Medicine ,030212 general & internal medicine ,Limit (mathematics) ,Simple (philosophy) ,Sequence ,business.industry ,Hybrid algorithm ,Femoral Artery ,Coronary Occlusion ,Chronic Disease ,Radial Artery ,Minification ,Cardiology and Cardiovascular Medicine ,business ,Algorithms ,Dual access - Abstract
Percutaneous recanalization of coronary chronic total occlusions (CTOs) traditionally relies on the use of dual access and large bore catheters, with trans-femoral approach adoption in most of the cases. Aim of this manuscript is to describe an alternative algorithm, that we called "Minimalistic Hybrid Algorithm", in order to minimize the use of double access, large bore catheters, and femoral approach thus reducing patient's discomfort and possibly procedural complications. This algorithm can be interpreted as an evolution of the classic "Hybrid Algorithm" and requires the operator to be confident with all techniques known in this conventional algorithm. Indeed, all possible techniques and approaches of the conventional hybrid approach to treat CTOs are included in a novel diagram for procedural strategy, which offers an alternative sequence of steps to limit, whenever possible, the invasiveness of the procedure. After dividing the cases in "simple" or "complex" CTO lesions according to the available complexity scores and to the "feeling", knowledge and expertise of the operator, a systematic description of the procedural steps is provided. This includes antegrade and retrograde approaches, as well as sub-intimal and intra-luminal techniques, in order to maintain the simpler single-catheter transradial strategies in the first line for the simple CTO, and the adoption of more complex, double access and transfemoral ones in the further steps. The minimalistic hybrid algorithm herein described is a possible alternative sequence of steps in the setting of CTO recanalization, with the potential of limiting the use of double access, large bore catheters, and femoral approach.
- Published
- 2019
- Full Text
- View/download PDF
8. Nationwide Outcomes of Octogenarians Following Open or Endovascular Management After Ruptured Abdominal Aortic Aneurysms
- Author
-
Alberga, Anna J., de Bruin, Jorg L., Bastos Gonçalves, Frederico, Karthaus, Eleonora G., Wilschut, Janneke A., van Herwaarden, Joost A., Wever, Jan J., Verhagen, Hence J. M., PJ, Van den Akker, GJ, Akkersdijk, GP, Akkersdijk, WL, Akkersdijk, MG, van Andringa de Kempenaer, CH, Arts, JA, Avontuur, OJ, Bakker, R, Balm, WB, Barendregt, JA, Bekken, MH, Bender, BL, Bendermacher, M, van den Berg, P, Berger, RJ, Beuk, JD, Blankensteijn, RJ, Bleker, JJ, Blok, AS, Bode, ME, Bodegom, KE, van der Bogt, AP, Boll, MH, Booster, BL, Borger van der Burg, GJ, de Borst, WT, Bos-van Rossum, J, Bosma, JM, Botman, LH, Bouwman, V, Brehm, MT, de Bruijn, JL, de Bruin, P, Brummel, JP, van Brussel, SE, Buijk, MA, Buijs, MG, Buimer, DH, Burger, HC, Buscher, E, Cancrinus, PH, Castenmiller, G, Cazander, AM, Coester, PH, Cuypers, JH, Daemen, I, Dawson, JE, Dierikx, ML, Dijkstra, J, Diks, MK, Dinkelman, M, Dirven, DE, Dolmans, RC, van Doorn, LM, van Dortmont, JW, Drouven, MM, van der Eb, D, Eefting, GJ, van Eijck, JW, Elshof, BH, Elsman, A, van der Elst, MI, van Engeland, RG, van Eps, MJ, Faber, WM, de Fijter, B, Fioole, TM, Fokkema, FA, Frans, WM, Fritschy, PH, Fung Kon Jin, RH, Geelkerken, WB, van Gent, GJ, Glade, B, Govaert, RP, Groenendijk, HG, de Groot, RF, van den Haak, EF, de Haan, GF, Hajer, JF, Hamming, ES, van Hattum, CE, Hazenberg, PP, Hedeman Joosten, JN, Helleman, LG, van der Hem, JM, Hendriks, JA, van Herwaarden, JM, Heyligers, JW, Hinnen, RJ, Hissink, GH, Ho, PT, den Hoed, MT, Hoedt, F, van Hoek, R, Hoencamp, WH, Hoffmann, W, Hogendoorn, AW, Hoksbergen, EJ, Hollander, M, Hommes, CJ, Hopmans, LC, Huisman, RG, Hulsebos, KM, Huntjens, MM, Idu, MJ, Jacobs, MF, van der Jagt, JR, Jansbeken, RJ, Janssen, HH, Jiang, SC, de Jong, TA, Jongbloed-Winkel, V, Jongkind, MR, Kapma, BP, Keller, A, Khodadade Jahrome, JK, Kievit, PL, Klemm, P, Klinkert, NA, Koedam, MJ, Koelemaij, JL, Kolkert, GG, Koning, OH, Koning, R, Konings, AG, Krasznai, RM, Krol, RH, Kropman, RR, Kruse, L, van der Laan, n MJ, van der Laa, JH, van Laanen, GW, van Lammeren, DA, Lamprou, JH, Lardenoye, GJ, Lauret, BJ, Leenders, DA, Legemate, VJ, Leijdekkers, MS, Lemson, MM, Lensvelt, MA, Lijkwan, RC, Lind, FT, van der Linden, PF, Liqui Lung, MJ, Loos, MC, Loubert, KM, van de Luijtgaarden, DE, Mahmoud, CG, Manshanden, EC, Mattens, R, Meerwaldt, BM, Mees, GC, von Meijenfeldt, TP, Menting, R, Metz, RC, Minnee, JC, de Mol van Otterloo, MJ, Molegraaf, YC, Montauban van Swijndregt, MJ, Morak, RH, van de Mortel, W, Mulder, SK, Nagesser, CC, Naves, JH, Nederhoed, AM, Nevenzel-Putters, AJ, de Nie, DH, Nieuwenhuis, J, Nieuwenhuizen, RC, van Nieuwenhuizen, D, Nio, VJ, Noyez, AP, Oomen, BI, Oranen, J, Oskam, HW, Palamba, AG, Peppelenbosch, AS, van Petersen, BJ, Petri, ME, Pierie, AJ, Ploeg, RA, Pol, ED, Ponfoort, IC, Post, PP, Poyck, A, Prent, S, ten Raa, JT, Raymakers, M, Reichart, BL, Reichmann, MM, Reijnen, JA, de Ridder, A, Rijbroek, MJ, van Rijn, RA, de Roo, EV, Rouwet, BR, Saleem, PB, Salemans, MR, van Sambeek, MG, Samyn, HP, van ‘t Sant, J, van Schaik, PM, van Schaik, DM, Scharn, MR, Scheltinga, A, Schepers, PM, Schlejen, FJ, Schlosser, FP, Schol, VP, Scholtes, O, Schouten, MA, Schreve, GW, Schurink, CJ, Sikkink, Slaa A, te, HJ, Smeets, L, Smeets, RR, Smeets, AA, de Smet, PC, Smit, TM, Smits, MG, Snoeijs, AO, Sondakh, MJ, Speijers, TJ, van der Steenhoven, SM, van Sterkenburg, DA, Stigter, RA, Stokmans, RP, Strating, GN, Stultiëns, JE, Sybrandy, JA, Teijink, BJ, Telgenkamp, M, Teraa, MJ, Testroote, T, Tha-In, RM, The, WJ, Thijsse, I, Thomassen, IF, Tielliu, RB, van Tongeren, RJ, Toorop, E, Tournoij, M, Truijers, K, Türkcan, RP, Tutein Nolthenius, Ç, Ünlü, RH, Vaes, AA, Vafi, AC, Vahl, EJ, Veen, HT, Veger, MG, Veldman, S, Velthuis, HJ, Verhagen, BA, Verhoeven, CF, Vermeulen, EG, Vermeulen, BP, Vierhout, RJ, van der Vijver-Coppen, MJ, Visser, JA, van der Vliet, CJ, Vlijmen—van Keulen, R, Voorhoeve, JR, van der Vorst, AW, Vos, B, de Vos, CG, Vos, GA, Vos, MT, Voute, BH, Vriens, PW, Vriens, AC, de Vries, DK, de Vries, JP, de Vries, M, de Vries, C, van der Waal, EJ, Waasdorp, BM, Wallis de Vries, LA, van Walraven, JL, van Wanroij, MC, Warlé, W, van de Water, V, van Weel, AM, van Well, GM, Welten, RJ, Welten, JJ, Wever, AM, Wiersema, OR, Wikkeling, WI, Willaert, J, Wille, MC, Willems, EM, Willigendael, ED, Wilschut, W, Wisselink, ME, Witte, CH, Wittens, CY, Wong, R, Wouda, O, Yazar, KK, Yeung, CJ, Zeebregts, and ML, van Zeeland
- Abstract
Purpose: Octogenarians are known to have less-favorable outcomes following ruptured abdominal aortic aneurysm (rAAA) repair compared with their younger counterparts. Accurate information regarding perioperative outcomes following rAAA-repair is important to evaluate current treatment practice. The aim of this study was to evaluate perioperative outcomes of octogenarians and to identify factors associated with mortality and major complications after open surgical repair (OSR) or endovascular aneurysm repair (EVAR) of a rAAA using nationwide, real-world, contemporary data.Methods: All patients that underwent EVAR or OSR of an infrarenal or juxtarenal rAAA between January 1, 2013, and December 31, 2018, were prospectively registered in the Dutch Surgical Aneurysm Audit (DSAA) and included in this study. The primary outcome was the comparison of perioperative outcomes of octogenarians versus non-octogenarians, including adjustment for confounders. Secondary outcomes were the identification of factors associated with mortality and major complications in octogenarians.Results: The study included 2879 patients, of which 1146 were treated by EVAR (382 octogenarians, 33%) and 1733 were treated by OSR (410 octogenarians, 24%). Perioperative mortality of octogenarians following EVAR was 37.2% versus 14.8% in non-octogenarians (adjusted OR=2.9, 95% CI=2.8–3.0) and 50.0% versus 29.4% following OSR (adjusted OR=2.2, 95% CI=2.2–2.3). Major complication rates of octogenarians were 55.4% versus 31.8% in non-octogenarians following EVAR (OR=2.7, 95% CI=2.1–3.4), and 68% versus 49% following OSR (OR=2.2, 95% CI=1.8–2.8). Following EVAR, 30.6% of the octogenarians had an uncomplicated perioperative course (UPC) versus 49.5% in non-octogenarians (OR=0.5, 95% CI=0.4–0.6), while following OSR, UPC rates were 20.7% in octogenarians versus 32.6% in non-octogenarians (OR=0.5, 95% CI=0.4–0.7). Cardiac or pulmonary comorbidity and loss of consciousness were associated with mortality and major complications in octogenarians. Interestingly, female octogenarians had lower mortality rates following EVAR than male octogenarians (adjusted OR=0.7, 95% CI=0.6–0.8).Conclusion: Based on this nationwide study with real-world registry data, mortality rates of octogenarians following ruptured AAA-repair were high, especially after OSR. However, a substantial proportion of these octogenarians following OSR and EVAR had an uneventful recovery. Known preoperative factors do influence perioperative outcomes and reflect current treatment practice.
- Published
- 2023
- Full Text
- View/download PDF
9. Nationwide Study to Predict Colonic Ischemia after Abdominal Aortic Aneurysm Repair in The Netherlands
- Author
-
Saskia Irene Willemsen, Martijn Geert ten Berge, Randolph George Statius van Eps, Hugo Thomas Christian Veger, Hans van Overhagen, Lukas Carolus van Dijk, Hein Putter, Jan Jacob Wever, L.H. Van den Akker, P.J. Van den Akker, G.J. Akkersdijk, G.P. Akkersdijk, W.L. Akkersdijk, M.G. van Andringa de Kempenaer, C.H. Arts, J.A. Avontuur, J.G. Baal, O.J. Bakker, R. Balm, W.B. Barendregt, M.H. Bender, B.L. Bendermacher, M. van den Berg, P. Berger, R.J. Beuk, J.D. Blankensteijn, R.J. Bleker, J.H. Bockel, M.E. Bodegom, K.E. Bogt, A.P. Boll, M.H. Booster, B.L. Borger van der Burg, G.J. de Borst, W.T. Bos-van Rossum, J. Bosma, J.M. Botman, L.H. Bouwman, J.C. Breek, V. Brehm, M.J. Brinckman, T.H. van den Broek, H.L. Brom, M.T. de Bruijn, J.L. de Bruin, P. Brummel, J.P. van Brussel, S.E. Buijk, M.G. Buimer, D.H. Burger, H.C. Buscher, G. den Butter, E. Cancrinus, P.H. Castenmiller, G. Cazander, H.M. Coveliers, P.H. Cuypers, J.H. Daemen, I. Dawson, A.F. Derom, A.R. Dijkema, J. Diks, M.K. Dinkelman, M. Dirven, D.E. Dolmans, R.C. van Doorn, L.M. van Dortmont, M.M. van der Eb, D. Eefting, G.J. van Eijck, J.W. Elshof, B.H. Elsman, A. van der Elst, M.I. van Engeland, R.G. van Eps, M.J. Faber, W.M. de Fijter, B. Fioole, W.M. Fritschy, R.H. Geelkerken, W.B. van Gent, G.J. Glade, B. Govaert, R.P. Groenendijk, H.G. de Groot, R.F. van den Haak, E.F. de Haan, G.F. Hajer, J.F. Hamming, E.S. van Hattum, C.E. Hazenberg, P.P. Hedeman Joosten, J.N. Helleman, L.G. van der Hem, J.M. Hendriks, J.A. van Herwaarden, J.M. Heyligers, J.W. Hinnen, R.J. Hissink, G.H. Ho, P.T. den Hoed, M.T. Hoedt, F. van Hoek, R. Hoencamp, W.H. Hoffmann, A.W. Hoksbergen, E.J. Hollander, L.C. Huisman, R.G. Hulsebos, K.M. Huntjens, M.M. Idu, M.J. Jacobs, M.F. van der Jagt, J.R. Jansbeken, R.J. Janssen, H.H. Jiang, S.C. de Jong, V. Jongkind, M.R. Kapma, B.P. Keller, A. Khodadade Jahrome, J.K. Kievit, P.L. Klemm, P. Klinkert, B. Knippenberg, N.A. Koedam, M.J. Koelemaij, J.L. Kolkert, G.G. Koning, O.H. Koning, A.G. Krasznai, R.M. Krol, R.H. Kropman, R.R. Kruse, L. van der Laan, M.J. van der Laan, J.H. van Laanen, J.H. Lardenoye, J.A. Lawson, D.A. Legemate, V.J. Leijdekkers, M.S. Lemson, M.M. Lensvelt, M.A. Lijkwan, R.C. Lind, F.T. van der Linden, P.F. Liqui Lung, M.J. Loos, M.C. Loubert, D.E. Mahmoud, C.G. Manshanden, E.C. Mattens, R. Meerwaldt, B.M. Mees, R. Metz, R.C. Minnee, J.C. de Mol van Otterloo, F.L. Moll, Y.C. Montauban van Swijndregt, M.J. Morak, R.H. van de Mortel, W. Mulder, S.K. Nagesser, C.C. Naves, J.H. Nederhoed, A.M. Nevenzel-Putters, A.J. de Nie, D.H. Nieuwenhuis, J. Nieuwenhuizen, R.C. van Nieuwenhuizen, D. Nio, A.P. Oomen, B.I. Oranen, J. Oskam, H.W. Palamba, A.G. Peppelenbosch, A.S. van Petersen, T.F. Peterson, B.J. Petri, M.E. Pierie, A.J. Ploeg, R.A. Pol, E.D. Ponfoort, P.P. Poyck, A. Prent, S. ten Raa, J.T. Raymakers, M. Reichart, B.L. Reichmann, M.M. Reijnen, A. Rijbroek, M.J. van Rijn, R.A. de Roo, E.V. Rouwet, C.G. Rupert, B.R. Saleem, M.R. van Sambeek, M.G. Samyn, H.P. van’t Sant, J. van Schaik, P.M. van Schaik, D.M. Scharn, M.R. Scheltinga, A. Schepers, P.M. Schlejen, F.J. Schlosser, F.P. Schol, O. Schouten, M.H. Schreinemacher, M.A. Schreve, G.W. Schurink, C.J. Sikkink, M.P. Siroen, A. te Slaa, H.J. Smeets, L. Smeets, A.A. de Smet, P. de Smit, P.C. Smit, T.M. Smits, M.G. Snoeijs, A.O. Sondakh, T.J. van der Steenhoven, S.M. van Sterkenburg, D.A. Stigter, H. Stigter, R.P. Strating, G.N. Stultiëns, J.E. Sybrandy, J.A. Teijink, B.J. Telgenkamp, M.J. Testroote, R.M. The, W.J. Thijsse, I.F. Tielliu, R.B. van Tongeren, R.J. Toorop, J.H. Tordoir, E. Tournoij, M. Truijers, K. Türkcan, R.P. Tutein Nolthenius, Ç. Ünlü, A.A. Vafi, A.C. Vahl, E.J. Veen, H.T. Veger, M.G. Veldman, H.J. Verhagen, B.A. Verhoeven, C.F. Vermeulen, E.G. Vermeulen, B.P. Vierhout, M.J. Visser, J.A. van der Vliet, C.J. Vlijmen-van Keulen, H.G. Voesten, R. Voorhoeve, A.W. Vos, B. de Vos, G.A. Vos, B.H. Vriens, P.W. Vriens, A.C. de Vries, J.P. de Vries, M. de Vries, C. van der Waal, E.J. Waasdorp, B.M. Wallis de Vries, L.A. van Walraven, J.L. van Wanroij, M.C. Warlé, V. van Weel, A.M. van Well, G.M. Welten, R.J. Welten, J.J. Wever, A.M. Wiersema, O.R. Wikkeling, W.I. Willaert, J. Wille, M.C. Willems, E.M. Willigendael, W. Wisselink, M.E. Witte, C.H. Wittens, I.C. Wolf-de Jonge, O. Yazar, C.J. Zeebregts, M.L. van Zeeland, TechMed Centre, Multi-Modality Medical Imaging, Technical Medicine, Surgery, ACS - Atherosclerosis & ischemic syndromes, Medical Biochemistry, ACS - Diabetes & metabolism, Amsterdam Gastroenterology Endocrinology Metabolism, APH - Methodology, and APH - Quality of Care
- Subjects
Male ,Time Factors ,medicine.medical_treatment ,Vascular damage Radboud Institute for Health Sciences [Radboudumc 16] ,030204 cardiovascular system & hematology ,Logistic regression ,Endovascular aneurysm repair ,030218 nuclear medicine & medical imaging ,0302 clinical medicine ,Risk Factors ,Colon/blood supply ,80 and over ,Medicine ,Aortic Aneurysm, Abdominal/surgery ,Netherlands ,Aged, 80 and over ,Univariate analysis ,education.field_of_study ,Endovascular Procedures ,General Medicine ,Middle Aged ,Abdominal aortic aneurysm ,Aortic Aneurysm ,Treatment Outcome ,Elective Surgical Procedures ,Cardiology ,Female ,Cardiology and Cardiovascular Medicine ,Cohort study ,medicine.medical_specialty ,Colon ,Population ,Mesenteric Ischemia/diagnosis ,Risk Assessment ,03 medical and health sciences ,Blood Vessel Prosthesis Implantation ,Aneurysm ,Internal medicine ,Humans ,Endovascular Procedures/adverse effects ,cardiovascular diseases ,Blood Vessel Prosthesis Implantation/adverse effects ,education ,Aged ,Retrospective Studies ,business.industry ,Colonic ischemia ,Abdominal/surgery ,medicine.disease ,Mesenteric Ischemia ,Surgery ,Emergencies ,business ,Aortic Aneurysm, Abdominal - Abstract
BACKGROUND: Colonic ischemia remains a severe complication after abdominal aortic aneurysm (AAA) repair and is associated with a high mortality. With open repair being one of the main risk factors of colonic ischemia, deciding between endovascular or open aneurysm repair should be based on tailor-made medicine. This study aims to identify high-risk patients of colonic ischemia, a risk that can be taken into account while deciding on AAA treatment strategy.METHODS: A nationwide population-based cohort study of 9,433 patients who underwent an AAA operation between 2014 and 2016 was conducted. Potential risk factors were determined by reviewing prior studies and univariate analysis. With logistic regression analysis, independent predictors of intestinal ischemia were established. These variables were used to form a prediction model.RESULTS: Intestinal ischemia occurred in 267 patients (2.8%). Occurrence of intestinal ischemia was seen significantly more in open repair versus endovascular aneurysm repair (7.6% vs. 0.9%; P < 0.001). This difference remained significant after stratification by urgency of the procedure, in both intact open (4.2% vs. 0.4%; P < 0.001) and ruptured open repair (15.0% vs. 6.2%); P < 0.001). Rupture of the AAA was the most important predictor of developing intestinal ischemia (odds ratio [OR], 5.9, 95% confidence interval [CI] 4.4-8.0), followed by having a suprarenal AAA (OR 3.4; CI 1.1-10.6). Associated procedural factors were open repair (OR 2.8; 95% CI 1.9-4.2), blood loss >1L (OR 3.6; 95% CI 1.7-7.5), and prolonged operating time (OR 2.0; 95% CI 1.4-2.8). Patient characteristics included having peripheral arterial disease (OR 2.4; 95% CI 1.3-4.4), female gender (OR 1.7; 95% CI 1.2-2.4), renal insufficiency (OR 1.7; 1.3-2.2), and pulmonary history (OR 1.6; 95% CI 1.2-2.2). Age CONCLUSIONS: One of the main risk factors is open repair. Several other risk factors can contribute to developing colonic ischemia after AAA repair. The proposed prediction model can be used to identify patients at high risk for developing colonic ischemia. With the current trend in AAA repair leaning toward open repair for better long-term results, our prediction model allows a better informed decision can be made in AAA treatment strategy.
- Published
- 2021
10. National Numbers of Secondary Aortic Reinterventions after Primary Abdominal Aortic Aneurysm Surgery from the Dutch Surgical Aneurysm Audit
- Author
-
Eleonora G. Karthaus, Anco Vahl, Bernard H.P. Elsman, Michel W.J.M. Wouters, Gert J. de Borst, Jaap F. Hamming, P.J. Van den Akker, G.J. Akkersdijk, G.P. Akkersdijk, W.L. Akkersdijk, M.G. van Andringa de Kempenaer, C.H. Arts, J.A. Avontuur, O.J. Bakker, R. Balm, W.B. Barendregt, J.A. Bekken, M.H. Bender, B.L. Bendermacher, M. van den Berg, P. Berger, R.J. Beuk, J.D. Blankensteijn, R.J. Bleker, J.J. Blok, A.S. Bode, M.E. Bodegom, K.E. van der Bogt, A.P. Boll, M.H. Booster, B.L. Borger van der Burg, G.J. de Borst, W.T. Bos-van Rossum, J. Bosma, J.M. Botman, L.H. Bouwman, V. Brehm, M.T. de Bruijn, J.L. de Bruin, P. Brummel, J.P. van Brussel, S.E. Buijk, M.A. Buijs, M.G. Buimer, D.H. Burger, H.C. Buscher, E. Cancrinus, P.H. Castenmiller, G. Cazander, A.M. Coester, P.H. Cuypers, J.H. Daemen, I. Dawson, J.E. Dierikx, M.L. Dijkstra, J. Diks, M.K. Dinkelman, M. Dirven, D.E. Dolmans, R.C. van Doorn, L.M. van Dortmont, J.W. Drouven, M.M. van der Eb, D. Eefting, G.J. van Eijck, J.W. Elshof, B.H. Elsman, A. van der Elst, M.I. van Engeland, R.G. van Eps, M.J. Faber, W.M. de Fijter, B. Fioole, T.M. Fokkema, F.A. Frans, W.M. Fritschy, P.H. Fung Kon Jin, R.H. Geelkerken, W.B. van Gent, G.J. Glade, B. Govaert, R.P. Groenendijk, H.G. de Groot, R.F. van den Haak, E.F. de Haan, G.F. Hajer, J.F. Hamming, E.S. van Hattum, C.E. Hazenberg, P.P. Hedeman Joosten, J.N. Helleman, L.G. van der Hem, J.M. Hendriks, J.A. van Herwaarden, J.M. Heyligers, J.W. Hinnen, R.J. Hissink, G.H. Ho, P.T. den Hoed, M.T. Hoedt, F. van Hoek, R. Hoencamp, W.H. Hoffmann, W. Hogendoorn, A.W. Hoksbergen, E.J. Hollander, M. Hommes, C.J. Hopmans, L.C. Huisman, R.G. Hulsebos, K.M. Huntjens, M.M. Idu, M.J. Jacobs, M.F. van der Jagt, J.R. Jansbeken, R.J. Janssen, H.H. Jiang, S.C. de Jong, T.A. Jongbloed-Winkel, V. Jongkind, M.R. Kapma, B.P. Keller, A. Khodadade Jahrome, J.K. Kievit, P.L. Klemm, P. Klinkert, N.A. Koedam, M.J. Koelemaij, J.L. Kolkert, G.G. Koning, O.H. Koning, R. Konings, A.G. Krasznai, R.M. Krol, R.H. Kropman, R.R. Kruse, L. van der Laan, M.J. van der Laan, J.H. van Laanen, G.W. van Lammeren, D.A. Lamprou, J.H. Lardenoye, G.J. Lauret, B.J. Leenders, D.A. Legemate, V.J. Leijdekkers, M.S. Lemson, M.M. Lensvelt, M.A. Lijkwan, R.C. Lind, F.T. van der Linden, P.F. Liqui Lung, M.J. Loos, M.C. Loubert, K.M. van de Luijtgaarden, D.E. Mahmoud, C.G. Manshanden, E.C. Mattens, R. Meerwaldt, B.M. Mees, G.C. von Meijenfeldt, T.P. Menting, R. Metz, R.C. Minnee, J.C. de Mol van Otterloo, M.J. Molegraaf, Y.C. Montauban van Swijndregt, M.J. Morak, R.H. van de Mortel, W. Mulder, S.K. Nagesser, C.C. Naves, J.H. Nederhoed, A.M. Nevenzel-Putters, A.J. de Nie, D.H. Nieuwenhuis, J. Nieuwenhuizen, R.C. van Nieuwenhuizen, D. Nio, V.J. Noyez, A.P. Oomen, B.I. Oranen, J. Oskam, H.W. Palamba, A.G. Peppelenbosch, A.S. van Petersen, B.J. Petri, M.E. Pierie, A.J. Ploeg, R.A. Pol, E.D. Ponfoort, I.C. Post, P.P. Poyck, A. Prent, S. ten Raa, J.T. Raymakers, M. Reichart, B.L. Reichmann, M.M. Reijnen, J.A. de Ridder, A. Rijbroek, M.J. van Rijn, R.A. de Roo, E.V. Rouwet, B.R. Saleem, P.B. Salemans, M.R. van Sambeek, M.G. Samyn, H.P. van't Sant, J. van Schaik, P.M. van Schaik, D.M. Scharn, M.R. Scheltinga, A. Schepers, P.M. Schlejen, F.J. Schlosser, F.P. Schol, V.P. Scholtes, O. Schouten, M.A. Schreve, G.W. Schurink, C.J. Sikkink, A. te Slaa, H.J. Smeets, L. Smeets, R.R. Smeets, A.A. de Smet, P.C. Smit, T.M. Smits, M.G. Snoeijs, A.O. Sondakh, M.J. Speijers, T.J. van der Steenhoven, S.M. van Sterkenburg, D.A. Stigter, R.A. Stokmans, R.P. Strating, G.N. Stultiëns, J.E. Sybrandy, J.A. Teijink, B.J. Telgenkamp, M. Teraa, M.J. Testroote, T. Tha-In, R.M. The, W.J. Thijsse, I. Thomassen, I.F. Tielliu, R.B. van Tongeren, R.J. Toorop, E. Tournoij, M. Truijers, K. Türkcan, R.P. Tutein Nolthenius, Ç. Ünlü, R.H. Vaes, A.A. Vafi, A.C. Vahl, E.J. Veen, H.T. Veger, M.G. Veldman, S. Velthuis, H.J. Verhagen, B.A. Verhoeven, C.F. Vermeulen, E.G. Vermeulen, B.P. Vierhout, R.J. van der Vijver-Coppen, M.J. Visser, J.A. van der Vliet, C.J. Vlijmen-van Keulen, R. Voorhoeve, J.R. van der Vorst, A.W. Vos, B. de Vos, C.G. Vos, G.A. Vos, M.T. Voute, B.H. Vriens, P.W. Vriens, A.C. de Vries, D.K. de Vries, J.P. de Vries, M. de Vries, C. van der Waal, E.J. Waasdorp, W. de Vries, L.A. van Walraven, J.L. van Wanroij, M.C. Warlé, W. van de Water, V. van Weel, A.M. van Well, G.M. Welten, R.J. Welten, J.J. Wever, A.M. Wiersema, O.R. Wikkeling, W.I. Willaert, J. Wille, M.C. Willems, E.M. Willigendael, E.D. Wilschut, W. Wisselink, M.E. Witte, C.H. Wittens, C.Y. Wong, R. Wouda, O. Yazar, K.K. Yeung, C.J. Zeebregts, M.L. van Zeeland, Surgery, ACS - Atherosclerosis & ischemic syndromes, Pathology, VU University medical center, Pediatrics, Dermatology, ACS - Microcirculation, ACS - Diabetes & metabolism, Amsterdam Gastroenterology Endocrinology Metabolism, Multi-Modality Medical Imaging, Technical Medicine, RS: CAPHRI - R5 - Optimising Patient Care, and Epidemiologie
- Subjects
Male ,Time Factors ,medicine.medical_treatment ,Vascular damage Radboud Institute for Health Sciences [Radboudumc 16] ,UT-Hybrid-D ,EVAR TRIAL 1 ,OPEN REPAIR ,030204 cardiovascular system & hematology ,Endovascular aneurysm repair ,030218 nuclear medicine & medical imaging ,Postoperative Complications ,0302 clinical medicine ,LONG-TERM OUTCOMES ,Risk Factors ,FAILURE ,Registries ,skin and connective tissue diseases ,Netherlands ,Aged, 80 and over ,Medical Audit ,Endovascular Procedures ,General Medicine ,EDITORS CHOICE ,Abdominal aortic aneurysm ,Treatment Outcome ,Cohort ,cardiovascular system ,INSTRUCTIONS ,Female ,Cardiology and Cardiovascular Medicine ,Reoperation ,medicine.medical_specialty ,Blood Vessel Prosthesis Implantation ,03 medical and health sciences ,Aneurysm ,medicine ,Humans ,Aged ,Surgical repair ,business.industry ,MORTALITY ,fungi ,Stent ,ENDOVASCULAR REPAIR ,Odds ratio ,medicine.disease ,Confidence interval ,Surgery ,body regions ,business ,SYSTEM ,Aortic Aneurysm, Abdominal - Abstract
Contains fulltext : 226469.pdf (Publisher’s version ) (Open Access) BACKGROUND: Long-term secondary aortic reinterventions (SARs) can be a sign of (lack of) effectiveness of abdominal aortic aneurysm (AAA) surgery. This study provides insight into the national number of SARs after primary AAA repair by endovascular aneurysm repair (EVAR) or by open surgical repair in the Netherlands. METHODS: Observational study included all patients undergoing SAR between 2016 and 2017, registered in the compulsory Dutch Surgical Aneurysm Audit (DSAA). The DSAA started in 2013, SARs are registered from 2016. Characteristics of SAR and postoperative outcomes (mortality/complications) were analyzed, stratified by urgency of SAR. Data of SARs were merged with data of their preceded primary AAA repair, registered in the DSAA after January 2013. In these patients undergoing SAR, treatment characteristics of the preceded primary AAA repair were additionally described, with focus on differences between stent grafts. RESULTS: Between 2016 and 2017, 691 patients underwent SAR, this concerned 9.3% of all AAA procedures (infrarenal/juxtarenal/suprarenal) in the Netherlands (77% elective/11% acute symptomatic/12% ruptured). Endoleak (60%) was the most frequent indication for SAR. SARs were performed with EVAR in 66%. Postoperative mortalities after SAR were 3.4%, 11%, and 29% in elective, acute symptomatic, and ruptured patients, respectively. In 26% (n = 181) of the patients undergoing SAR their primary AAA repair was performed after January 2013 and data of primary and SAR procedures could be merged. In 93% (n = 136), primary AAA repair was EVAR. Endografts primarily used were nitinol/polyester (62%), nitinol/polytetrafluoroethylene (8%), endovascular sealing (21%), and others (9%), compared with their national market share of 76% (odds ratio [OR], 0.52; 95% confidence interval [CI], 0.38-0.71), 15% (OR, 0.50; CI, 0.29-0.89), 4.9% (OR, 5.04; CI, 3.44-7.38), and 4.1% (OR, 2.81; CI, 1.66-4.74), respectively. CONCLUSIONS: In the Netherlands, about one-tenth of the annual AAA procedures concerns an SAR. A quarter of this cohort had an SAR within 1-5 years after their primary AAA repair. Most SARs followed after primary EVAR procedures, in which an overrepresentation of endovascular sealing grafts was seen. Postoperative mortality after SAR is comparable with primary AAA repair.
- Published
- 2020
- Full Text
- View/download PDF
11. A Composite Measure for Quality of Care in Patients with Symptomatic Carotid Stenosis Using Textbook Outcome
- Author
-
Laurien S. Kuhrij, Eleonora G. Karthaus, Anco C. Vahl, Martine C.M. Willems, Jan W. Elshof, Gert J. de Borst, P.J. Van den Akker, G.J. Akkersdijk, G.P. Akkersdijk, W.L. Akkersdijk, M.G. van Andringa de Kempenaer, C.H. Arts, J.A. Avontuur, O.J. Bakker, R. Balm, W.B. Barendregt, J.A. Bekken, M.H. Bender, B.L. Bendermacher, M. van den Berg, P. Berger, R.J. Beuk, J.D. Blankensteijn, R.J. Bleker, J.J. Blok, A.S. Bode, M.E. Bodegom, K.E. van der Bogt, A.P. Boll, M.H. Booster, B.L. Borger van der Burg, G.J. de Borst, W.T. Bos-van Rossum, J. Bosma, J.M. Botman, L.H. Bouwman, V. Brehm, M.T. de Bruijn, J.L. de Bruin, P. Brummel, J.P. van Brussel, S.E. Buijk, M.A. Buijs, M.G. Buimer, D.H. Burger, H.C. Buscher, E. Cancrinus, P.H. Castenmiller, G. Cazander, A.M. Coester, P.H. Cuypers, J.H. Daemen, I. Dawson, J.E. Dierikx, M.L. Dijkstra, J. Diks, M.K. Dinkelman, M. Dirven, D.E. Dolmans, R.C. van Doorn, L.M. van Dortmont, J.W. Drouven, M.M. van der Eb, D. Eefting, G.J. van Eijck, J.W. Elshof, B.H. Elsman, A. van der Elst, M.I. van Engeland, R.G. van Eps, M.J. Faber, W.M. de Fijter, B. Fioole, T.M. Fokkema, F.A. Frans, W.M. Fritschy, P.H. Fung Kon Jin, R.H. Geelkerken, W.B. van Gent, G.J. Glade, B. Govaert, R.P. Groenendijk, H.G. de Groot, R.F. van den Haak, E.F. de Haan, G.F. Hajer, J.F. Hamming, E.S. van Hattum, C.E. Hazenberg, P.P. Hedeman Joosten, J.N. Helleman, L.G. van der Hem, J.M. Hendriks, J.A. van Herwaarden, J.M. Heyligers, J.W. Hinnen, R.J. Hissink, G.H. Ho, P.T. den Hoed, M.T. Hoedt, F. van Hoek, R. Hoencamp, W.H. Hoffmann, W. Hogendoorn, A.W. Hoksbergen, E.J. Hollander, M. Hommes, C.J. Hopmans, L.C. Huisman, R.G. Hulsebos, K.M. Huntjens, M.M. Idu, M.J. Jacobs, M.F. van der Jagt, J.R. Jansbeken, R.J. Janssen, H.H. Jiang, S.C. de Jong, T.A. Jongbloed-Winkel, V. Jongkind, M.R. Kapma, B.P. Keller, A. Khodadade Jahrome, J.K. Kievit, P.L. Klemm, P. Klinkert, N.A. Koedam, M.J. Koelemaij, J.L. Kolkert, G.G. Koning, O.H. Koning, R. Konings, A.G. Krasznai, R.M. Krol, R.H. Kropman, R.R. Kruse, L. van der Laan, M.J. van der Laan, J.H. van Laanen, G.W. van Lammeren, D.A. Lamprou, J.H. Lardenoye, G.J. Lauret, B.J. Leenders, D.A. Legemate, V.J. Leijdekkers, M.S. Lemson, M.M. Lensvelt, M.A. Lijkwan, R.C. Lind, F.T. van der Linden, P.F. Liqui Lung, M.J. Loos, M.C. Loubert, K.M. van de Luijtgaarden, D.E. Mahmoud, C.G. Manshanden, E.C. Mattens, R. Meerwaldt, B.M. Mees, G.C. von Meijenfeldt, T.P. Menting, R. Metz, R.C. Minnee, J.C. de Mol van Otterloo, M.J. Molegraaf, Y.C. Montauban van Swijndregt, M.J. Morak, R.H. van de Mortel, W. Mulder, S.K. Nagesser, C.C. Naves, J.H. Nederhoed, A.M. Nevenzel-Putters, A.J. de Nie, D.H. Nieuwenhuis, J. Nieuwenhuizen, R.C. van Nieuwenhuizen, D. Nio, V.J. Noyez, A.P. Oomen, B.I. Oranen, J. Oskam, H.W. Palamba, A.G. Peppelenbosch, A.S. van Petersen, B.J. Petri, M.E. Pierie, A.J. Ploeg, R.A. Pol, E.D. Ponfoort, I.C. Post, P.P. Poyck, A. Prent, S. ten Raa, J.T. Raymakers, M. Reichart, B.L. Reichmann, M.M. Reijnen, J.A. de Ridder, A. Rijbroek, M.J. van Rijn, R.A. de Roo, E.V. Rouwet, B.R. Saleem, P.B. Salemans, M.R. van Sambeek, M.G. Samyn, H.P. van ’t Sant, J. van Schaik, P.M. van Schaik, D.M. Scharn, M.R. Scheltinga, A. Schepers, P.M. Schlejen, F.J. Schlosser, F.P. Schol, V.P. Scholtes, O. Schouten, M.A. Schreve, G.W. Schurink, C.J. Sikkink, A. te Slaa, H.J. Smeets, L. Smeets, R.R. Smeets, A.A. de Smet, P.C. Smit, T.M. Smits, M.G. Snoeijs, A.O. Sondakh, M.J. Speijers, T.J. van der Steenhoven, S.M. van Sterkenburg, D.A. Stigter, R.A. Stokmans, R.P. Strating, G.N. Stultiëns, J.E. Sybrandy, J.A. Teijink, B.J. Telgenkamp, M. Teraa, M.J. Testroote, T. Tha-In, R.M. The, W.J. Thijsse, I. Thomassen, I.F. Tielliu, R.B. van Tongeren, R.J. Toorop, E. Tournoij, M. Truijers, K. Türkcan, R.P. Tutein Nolthenius, Ç. Ünlü, R.H. Vaes, A.A. Vafi, A.C. Vahl, E.J. Veen, H.T. Veger, M.G. Veldman, S. Velthuis, H.J. Verhagen, B.A. Verhoeven, C.F. Vermeulen, E.G. Vermeulen, B.P. Vierhout, R.J. van der Vijver-Coppen, M.J. Visser, J.A. van der Vliet, C.J. Vlijmen - van Keulen, R. Voorhoeve, J.R. van der Vorst, A.W. Vos, B. de Vos, C.G. Vos, G.A. Vos, M.T. Voute, B.H. Vriens, P.W. Vriens, A.C. de Vries, D.K. de Vries, J.P. de Vries, M. de Vries, C. van der Waal, E.J. Waasdorp, B.M. Wallis de Vries, L.A. van Walraven, J.L. van Wanroij, M.C. Warlé, W. van de Water, V. van Weel, A.M. van Well, G.M. Welten, R.J. Welten, J.J. Wever, A.M. Wiersema, O.R. Wikkeling, W.I. Willaert, J. Wille, M.C. Willems, E.M. Willigendael, E.D. Wilschut, W. Wisselink, M.E. Witte, C.H. Wittens, C.Y. Wong, R. Wouda, O. Yazar, K.K. Yeung, C.J. Zeebregts, M.L. van Zeeland, Surgery, ACS - Atherosclerosis & ischemic syndromes, Pathology, VU University medical center, Pediatrics, ACS - Microcirculation, ACS - Diabetes & metabolism, Multi-Modality Medical Imaging, Technical Medicine, RS: CAPHRI - R5 - Optimising Patient Care, Epidemiologie, Graduate School, ANS - Neurovascular Disorders, APH - Methodology, and APH - Quality of Care
- Subjects
Male ,Time Factors ,medicine.medical_treatment ,Vascular damage Radboud Institute for Health Sciences [Radboudumc 16] ,Psychological intervention ,UT-Hybrid-D ,Carotid endarterectomy ,030204 cardiovascular system & hematology ,030230 surgery ,Logistic regression ,0302 clinical medicine ,Risk Factors ,Carotid Stenosis ,Registries ,Stroke ,Netherlands ,Outcome ,Aged, 80 and over ,RISK ,Endarterectomy, Carotid ,ENDARTERECTOMY ,Middle Aged ,Outcome and Process Assessment, Health Care ,Treatment Outcome ,Ischemic Attack, Transient ,Female ,Cardiology and Cardiovascular Medicine ,medicine.medical_specialty ,Funnel plot ,Postoperative Hemorrhage ,Patient Readmission ,03 medical and health sciences ,Case mix index ,Internal medicine ,medicine ,Humans ,HOSPITAL QUALITY ,Healthcare Disparities ,Aged ,Quality Indicators, Health Care ,business.industry ,Quality of care ,22/2 OA procedure ,Length of Stay ,medicine.disease ,Comorbidity ,Cranial Nerve Diseases ,Stenosis ,Surgery ,business - Abstract
Contains fulltext : 226467.pdf (Publisher’s version ) (Closed access) OBJECTIVE: Composite measures may better objectify hospital performance than individual outcome measures (IOM). Textbook outcome (TO) is an outcome measure achieved for an individual patient when all undesirable outcomes are absent. The aim of this study was to assess TO as an additional outcome measure to evaluate quality of care in symptomatic patients treated by carotid endarterectomy (CEA). METHODS: All symptomatic patients treated by CEA in 2018, registered in the Dutch Audit for Carotid Interventions, were included. TO was defined as a composite of the absence of 30 day mortality, neurological events (any stroke or transient ischaemic attack [TIA]), cranial nerve deficit, haemorrhage, 30 day readmission, prolonged length of stay (LOS; > 5 days) and any other surgical complication. Multivariable logistic regression was used to identify covariables associated with achieving TO, which were used for casemix adjustment for hospital comparison. For each hospital, an observed vs. expected number of events ratio (O/E ratio) was calculated and plotted in a funnel plot with 95% control limits. RESULTS: In total, 70.7% of patients had a desired outcome within 30 days after CEA and therefore achieved TO. Prolonged LOS was the most common parameter (85%) and mortality the least common (1.1%) for not achieving TO. Covariates associated with achieving TO were younger age, the absence of pulmonary comorbidity, higher haemoglobin levels, and TIA as index event. In the case mix adjusted funnel plot, the O/E ratios between hospitals ranged between 0.63 and 1.27, with two hospitals revealing a statistically significantly lower rate of TO (with O/E ratios of 0.63 and 0.66). CONCLUSION: In the Netherlands, most patients treated by CEA achieve TO. Variation between hospitals in achieving TO might imply differences in performance. TO may be used as an additive to the pre-existing IOM, especially in surgical care with low baseline risk such as CEA.
- Published
- 2020
- Full Text
- View/download PDF
12. First report of the use of long-tapered sirolimus-eluting coronary stent for the treatment of chronic total occlusions with the hybrid algorithm
- Author
-
José P.S. Henriques, Flavio Ribichini, Jurriën M. ten Berg, Antonio Colombo, Frank D. Eefting, Benno J. Rensing, Jan Peter van Kuijk, Floris S. van den Brink, Enrico Poletti, Lorenzo Azzalini, Vincent J. Nijenhuis, Maarten J. Suttorp, Pierfrancesco Agostoni, Jan Van der Heyden, Carlo Zivelonghi, Amsterdam Cardiovascular Sciences, Cardiology, and ACS - Atherosclerosis & ischemic syndromes
- Subjects
Male ,stable angina ,medicine.medical_specialty ,Percutaneous ,Time Factors ,medicine.medical_treatment ,030204 cardiovascular system & hematology ,Prosthesis Design ,Lesion ,03 medical and health sciences ,0302 clinical medicine ,Coronary stent ,Medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,In patient ,030212 general & internal medicine ,Angioplasty, Balloon, Coronary ,Vascular Patency ,Aged ,Retrospective Studies ,Sirolimus ,business.industry ,Stent ,chronic coronary total occlusion ,Cardiovascular Agents ,Drug-Eluting Stents ,General Medicine ,Middle Aged ,Surgery ,Treatment Outcome ,Coronary Occlusion ,drug eluting stent ,Drug-eluting stent ,Chronic Disease ,Distal segment ,Female ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,business ,medicine.drug - Abstract
BACKGROUND Coronary chronic total occlusions (CTO) usually coexist with diffusely diseased coronary segments proximal and/or distal to the CTO segment. During percutaneous treatment of CTO, multiple overlapping stents are often needed to treat these long lesions. OBJECTIVES Aim of this study is to report the first use of long, tapered coronary sirolimus-eluting stents (SES) in this setting. METHODS AND RESULTS This is a retrospective analysis of 100 consecutive patients undergoing CTO recanalization following the hybrid algorithm. Procedural success rate was 89% (11 failures). Among the successful cases, "conventional" drug-eluting stents(DES) were used in 40(44.9%) patients, while in 49(55%) patients long-tapered SES were attempted with a success rate of 98% (1 cross-over to regular stents). Total stent length in the long-tapered DES group was higher compared to the "conventional" stenting group (76 ± 28 mm vs 46 ± 22 mm, P
- Published
- 2018
- Full Text
- View/download PDF
13. Veno-arterial extracorporeal membrane oxygenation in addition to primary PCI in patients presenting with ST-elevation myocardial infarction
- Author
-
A. D. Magan, J.P. van Kuijk, Erik Scholten, Peter G. Noordzij, J. M. ten Berg, F. S. van den Brink, J.A.S. Van Der Heyden, Carlo Zivelonghi, Peter M. Klein, M. J. Suttorp, B. R. Rensing, Pierfrancesco Agostoni, and Frank D. Eefting
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,030204 cardiovascular system & hematology ,STEMI ,Coronary artery disease ,03 medical and health sciences ,0302 clinical medicine ,Left coronary artery ,medicine.artery ,Internal medicine ,Extracorporeal membrane oxygenation ,Medicine ,030212 general & internal medicine ,Myocardial infarction ,Survival rate ,Cardiogenic Shock ,business.industry ,Circulatory Support ,Cardiogenic shock ,Percutaneous coronary intervention ,medicine.disease ,surgical procedures, operative ,Right coronary artery ,Cardiology ,Original Article ,ECMO ,Cardiology and Cardiovascular Medicine ,business - Abstract
Introduction Primary percutaneous coronary intervention (pPCI) in ST-elevation myocardial infarction (STEMI) can cause great haemodynamic instability. Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) can provide haemodynamic support in patients with STEMI but data on outcome and complications are scarce. Methods An in-hospital registry was conducted enrolling all patients receiving VA-ECMO. Patients were analysed for medical history, mortality, neurological outcome, complications and coronary artery disease. Results Between 2011 and 2016, 12 patients underwent pPCI for STEMI and received VA-ECMO for haemodynamic support. The majority of the patients were male (10/12) with a median age of 63 (47–75) years and 4 of the 12 patients had a history of coronary artery disease. A cardiac arrest was witnessed in 11 patients. The left coronary artery was compromised in 8 patients and 4 had right coronary artery disease. All patients were in Killip class IV. Survival to discharge was 67% (8/12), 1‑year survival was 42% (5/12), 2 patients have not yet reached the 1‑year survival point but are still alive and 1 patient died within a year after discharge. All-cause mortality was 42% (5/12) of which mortality on ECMO was 33% (4/12). Patient-related complications occurred in 6 of the 12 patients: 1 patient suffered major neurological impairment, 2 patients suffered haemorrhage at the cannula site, 2 patients had limb ischaemia and 1 patient had a haemorrhage elsewhere. There were no VA-ECMO hardware malfunctions. Conclusion VA-ECMO in pPCI for STEMI has a high survival rate and neurological outcome is good, even when the patient is admitted with a cardiac arrest.
- Published
- 2017
- Full Text
- View/download PDF
14. Outcomes after foot surgery in people with a diabetic foot ulcer and a 12-month follow-up
- Author
-
E. Lenselink, Samantha Holloway, and D. Eefting
- Subjects
Adult ,Reoperation ,medicine.medical_specialty ,Nursing (miscellaneous) ,030209 endocrinology & metabolism ,030204 cardiovascular system & hematology ,Amputation, Surgical ,Peripheral Arterial Disease ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Ischemia ,Risk Factors ,medicine ,Humans ,Aged ,Retrospective Studies ,Aged, 80 and over ,Wound Healing ,Foot ,business.industry ,Angioplasty ,Surgical debridement ,Middle Aged ,Toes ,medicine.disease ,Diabetic foot ,Diabetic Foot ,Surgery ,Diabetes Mellitus, Type 1 ,Treatment Outcome ,Diabetic foot ulcer ,Debridement ,Diabetes Mellitus, Type 2 ,Additional Surgery ,Additional procedure ,Fundamentals and skills ,Foot surgery ,business ,Organ Sparing Treatments ,Follow-Up Studies ,Month follow up ,Major amputation - Abstract
Objective: The aim of this study was to retrospectively measure the outcomes of foot-sparing surgery at one year follow-up for patients with diabetic foot ulcers (DFUs). We assessed wound healing and the need for further surgery in relation to the variables that influence healing. Method: Data were retrospectively collected by reviewing the electronic files of patients attending the Wound Expert Clinic (WEC). Outcomes of surgical debridement, toe, ray and transmetatarsal amputations were assessed. Results: A total of 129 cases in 121 patients were identified for inclusion. The results demonstrated that complete wound healing was reached in 52% (61/117) of the patients within 12 months. The need for additional surgery or for major amputation was 56% (n=72/129) and 30% (n=39/129) respectively. The need for an additional procedure was particularly high after surgical debridement (75%, 33/44) and transmetatarsal amputation (64%, 7/11). Risk factors for non-healing or for a major amputation were: infection (p=0.01), ischaemia (p=0.01), a history of peripheral arterial occlusive disease (pConclusion: The results of the study reveal some areas for improvement including timely revascularisation and performance of multiple debridement procedures if needed in order to save a limb
- Published
- 2017
- Full Text
- View/download PDF
15. Current Devices in Mitral Valve Replacement and Their Potential Complications
- Author
-
Bushra S. Rana, Frank D. Eefting, Livia L. Gheorghe, Dee Dee Wang, Leo Timmers, Martin J. Swaans, Benno J. Rensing, Nina Wunderlich, and Jorn Brouwer
- Subjects
mitral valve ,lcsh:Diseases of the circulatory (Cardiovascular) system ,medicine.medical_specialty ,Percutaneous ,medicine.medical_treatment ,mitral replacement ,complication ,Review ,030204 cardiovascular system & hematology ,Cardiovascular Medicine ,03 medical and health sciences ,0302 clinical medicine ,Mitral valve ,Medicine ,LVOT obstruction ,030212 general & internal medicine ,cardiovascular diseases ,Mitral valve repair ,Mitral regurgitation ,business.industry ,MitraClip ,Mitral valve replacement ,minimal invasive approach ,Surgery ,medicine.anatomical_structure ,lcsh:RC666-701 ,cardiovascular system ,Cardiology and Cardiovascular Medicine ,Complication ,Early phase ,business - Abstract
Mitral regurgitation is one of the most prevalent valvulopathies worldwide, and its surgical treatment is not feasible in all cases. The elderly and frail with several comorbidities and left ventricular dysfunction are often managed conservatively. Percutaneous treatment (repair or replacement) of the mitral valve has emerged as a potential option for those patients who are at a high risk for surgery. Mitral valve repair with the Mitraclip device proved both increased safety and mortality reduction in patients with severe mitral regurgitation. On the other hand, in the last decade, percutaneous mitral replacement opened new frontiers in the field of cardiac structural interventions. There are few mitral devices; some are in the early phase of development and some are waiting for CE mark of approval. The evolution of these devices was more complicated compared to the aortic technology due to the native mitral valve's complexity and access. This review aims to provide an overview of the current devices, their specific features, and their potential complications.
- Published
- 2020
16. Nationwide study of the treatment of mycotic abdominal aortic aneurysms comparing open and endovascular repair in The Netherlands
- Author
-
Quan Dang, Randolph G. Statius van Eps, Jan J. Wever, Hugo T.C. Veger, L.H. Van den Akker, P.J. Van den Akker, G.J. Akkersdijk, G.P. Akkersdijk, W.L. Akkersdijk, M.G. van Andringa de Kempenaer, C.H. Arts, J.A. Avontuur, J.G. Baal, O.J. Bakker, R. Balm, W.B. Barendregt, M.H. Bender, B.L. Bendermacher, M. van den Berg, P. Berger, R.J. Beuk, J.D. Blankensteijn, R.J. Bleker, J.H. Bockel, M.E. Bodegom, K.E. Bogt, A.P. Boll, M.H. Booster, B.L. Borger van der Burg, G.J. de Borst, W.T. Bos- van Rossum, J. Bosma, J.M. Botman, L.H. Bouwman, J.C. Breek, V. Brehm, M.J. Brinckman, T.H. van den Broek, H.L. Brom, M.T. de Bruijn, J.L. de Bruin, P. Brummel, J.P. van Brussel, S.E. Buijk, M.G. Buimer, D.H. Burger, H.C. Buscher, G. den Butter, E. Cancrinus, P.H. Castenmiller, G. Cazander, H.M. Coveliers, P.H. Cuypers, J.H. Daemen, I. Dawson, A.F. Derom, A.R. Dijkema, J. Diks, M.K. Dinkelman, M. Dirven, D.E. Dolmans, R.C. van Doorn, L.M. van Dortmont, M.M. van der Eb, D. Eefting, G.J. van Eijck, J.W. Elshof, B.H. Elsman, A. van der Elst, M.I. van Engeland, R.G. van Eps, M.J. Faber, W.M. de Fijter, B. Fioole, W.M. Fritschy, R.H. Geelkerken, W.B. van Gent, G.J. Glade, B. Govaert, R.P. Groenendijk, H.G. de Groot, R.F. van den Haak, E.F. de Haan, G.F. Hajer, J.F. Hamming, E.S. van Hattum, C.E. Hazenberg, P.P. Hedeman Joosten, J.N. Helleman, L.G. van der Hem, J.M. Hendriks, J.A. van Herwaarden, J.M. Heyligers, J.W. Hinnen, R.J. Hissink, G.H. Ho, P.T. den Hoed, M.T. Hoedt, F. van Hoek, R. Hoencamp, W.H. Hoffmann, A.W. Hoksbergen, E.J. Hollander, L.C. Huisman, R.G. Hulsebos, K.M. Huntjens, M.M. Idu, M.J. Jacobs, M.F. van der Jagt, J.R. Jansbeken, R.J. Janssen, H.H. Jiang, S.C. de Jong, V. Jongkind, M.R. Kapma, B.P. Keller, A. Khodadade Jahrome, J.K. Kievit, P.L. Klemm, P. Klinkert, B. Knippenberg, N.A. Koedam, M.J. Koelemaij, J.L. Kolkert, G.G. Koning, O.H. Koning, A.G. Krasznai, R.M. Krol, R.H. Kropman, R.R. Kruse, L. van der Laan, M.J. van der Laan, J.H. van Laanen, J.H. Lardenoye, J.A. Lawson, D.A. Legemate, V.J. Leijdekkers, M.S. Lemson, M.M. Lensvelt, M.A. Lijkwan, R.C. Lind, F.T. van der Linden, P.F. Liqui Lung, M.J. Loos, M.C. Loubert, D.E. Mahmoud, C.G. Manshanden, E.C. Mattens, R. Meerwaldt, B.M. Mees, R. Metz, R.C. Minnee, J.C. de Mol van Otterloo, F.L. Moll, Y.C. Montauban van Swijndregt, M.J. Morak, R.H. van de Mortel, W. Mulder, S.K. Nagesser, C.C. Naves, J.H. Nederhoed, A.M. Nevenzel-Putters, A.J. de Nie, D.H. Nieuwenhuis, J. Nieuwenhuizen, R.C. van Nieuwenhuizen, D. Nio, A.P. Oomen, B.I. Oranen, J. Oskam, H.W. Palamba, A.G. Peppelenbosch, A.S. van Petersen, T.F. Peterson, B.J. Petri, M.E. Pierie, A.J. Ploeg, R.A. Pol, E.D. Ponfoort, P.P. Poyck, A. Prent, S. ten Raa, J.T. Raymakers, M. Reichart, B.L. Reichmann, M.M. Reijnen, A. Rijbroek, M.J. van Rijn, R.A. de Roo, E.V. Rouwet, C.G. Rupert, B.R. Saleem, M.R. van Sambeek, M.G. Samyn, H.P. van ’t Sant, J. van Schaik, P.M. van Schaik, D.M. Scharn, M.R. Scheltinga, A. Schepers, P.M. Schlejen, F.J. Schlosser, F.P. Schol, O. Schouten, M.H. Schreinemacher, M.A. Schreve, G.W. Schurink, C.J. Sikkink, A. te Slaa, H.J. Smeets, L. Smeets, A.A. de Smet, P. de Smit, P.C. Smit, T.M. Smits, M.G. Snoeijs, A.O. Sondakh, T.J. van der Steenhoven, S.M. van Sterkenburg, D.A. Stigter, H. Stigter, R.P. Strating, G.N. Stultiëns, J.E. Sybrandy, J.A. Teijink, B.J. Telgenkamp, M.J. Testroote, R.M. The, W.J. Thijsse, I.F. Tielliu, R.B. van Tongeren, R.J. Toorop, J.H. Tordoir, E. Tournoij, M. Truijers, K. Türkcan, R.P. Tutein Nolthenius, Ç. Ünlü, A.A. Vafi, A.C. Vahl, E.J. Veen, H.T. Veger, M.G. Veldman, H.J. Verhagen, B.A. Verhoeven, C.F. Vermeulen, E.G. Vermeulen, B.P. Vierhout, M.J. Visser, J.A. van der Vliet, C.J. Vlijmen - van Keulen, H.G. Voesten, R. Voorhoeve, A.W. Vos, B. de Vos, G.A. Vos, B.H. Vriens, P.W. Vriens, A.C. de Vries, J.P. de Vries, M. de Vries, C. van der Waal, E.J. Waasdorp, B.M. Wallis de Vries, L.A. van Walraven, J.L. van Wanroij, M.C. Warlé, V. van Weel, A.M. van Well, G.M. Welten, R.J. Welten, J.J. Wever, A.M. Wiersema, O.R. Wikkeling, W.I. Willaert, J. Wille, M.C. Willems, E.M. Willigendael, W. Wisselink, M.E. Witte, C.H. Wittens, I.C. Wolf-de Jonge, O. Yazar, C.J. Zeebregts, M.L. van Zeeland, RS: CAPHRI - R5 - Optimising Patient Care, Epidemiologie, Surgery, ACS - Atherosclerosis & ischemic syndromes, Pathology, VU University medical center, Pediatrics, Dermatology, ACS - Microcirculation, ACS - Diabetes & metabolism, and Multi-Modality Medical Imaging
- Subjects
Male ,Clinical audit ,Time Factors ,SURGERY ,medicine.medical_treatment ,Vascular damage Radboud Institute for Health Sciences [Radboudumc 16] ,Abdominal aneurysm ,030204 cardiovascular system & hematology ,Endovascular aneurysm repair ,Postoperative Complications ,0302 clinical medicine ,Risk Factors ,Registries ,030212 general & internal medicine ,Mycotic ,Netherlands ,Medical Audit ,OUTCOMES ,Incidence ,Incidence (epidemiology) ,Endovascular Procedures ,Abdominal aorta ,Clinical course ,Infectious ,Middle Aged ,Anti-Bacterial Agents ,Treatment Outcome ,Female ,Cardiology and Cardiovascular Medicine ,medicine.medical_specialty ,Patient Readmission ,Risk Assessment ,Drug Administration Schedule ,Blood Vessel Prosthesis Implantation ,03 medical and health sciences ,Aneurysm ,THORACIC AORTA ,medicine.artery ,medicine ,Humans ,Aged ,Retrospective Studies ,ILIAC ARTERIES ,business.industry ,MORTALITY ,Retrospective cohort study ,medicine.disease ,n/a OA procedure ,Surgery ,VOLUME ,business ,Aneurysm, Infected ,Aortic Aneurysm, Abdominal - Abstract
Contains fulltext : 226470.pdf (Publisher’s version ) (Closed access) OBJECTIVE: Mycotic aneurysms of the abdominal aorta (MAAA) can be treated by open repair (OR) or endovascular aneurysm repair (EVAR). This nationwide study provides an overview of the situation of MAAA treatment in The Netherlands in 2016. METHODS: A retrospective cohort study was conducted with all centers that registered aortic abdominal aneurysms in the Dutch Surgical Aneurysm Audit in 2016. Questionnaires on 1-year outcomes were sent to all centers that treated patients with MAAA. The primary aim was to determine 30-day and 1-year mortality and morbidity of OR- and EVAR-treated patients. Morbidity was determined by the need for reoperations and the number of readmissions to the hospital. RESULTS: Twenty-six MAAA were detected in the Dutch Surgical Aneurysm Audit database of 2016, resulting in an incidence of 0.7% of all registered abdominal aortic aneurysms. The 30-day mortality for OR and EVAR treated patients was 1 in 13 and 0 in 13, respectively. Major and minor reinterventions within 30 days were needed for two (one OR and one EVAR) and two (one OR and one EVAR) patients, respectively. Two patients (15.4%) in the OR group and one patient (7.7%) in the EVAR group were readmitted to hospital within 30 days. In total, 1-year outcomes of 23 patients were available. In the OR group, one patient (9.1%) died in the first postoperative year. There was one major reintervention (removal of endoprosthesis and spiralvein reconstruction) in the EVAR group. Two patients (18.2%) treated with OR and two (16.7%) treated with EVAR required a minor reintervention. In both groups, four patients (OR, 36.4%; EVAR, 33.3%) were readmitted to hospital within 1 year postoperatively. CONCLUSIONS: Both OR- and EVAR-treated patients show acceptable clinical outcomes after 30 days and at the 1-year follow-up. Depending on the clinical course of the patient, EVAR may be considered in the management of this disease.
- Published
- 2020
- Full Text
- View/download PDF
17. Patients with a Ruptured Abdominal Aortic Aneurysm Are Better Informed in Hospitals with an 'EVAR-preferred' Strategy: An Instrumental Variable Analysis of the Dutch Surgical Aneurysm Audit
- Author
-
Eleonora G. Karthaus, Niki Lijftogt, Anco Vahl, Esmee M. van der Willik, Sonia Amodio, Erik W. van Zwet, Jaap F. Hamming, P.J. Van den Akker, G.J. Akkersdijk, G.P. Akkersdijk, W.L. Akkersdijk, M.G. van Andringa de Kempenaer, C.H. Arts, J.A. Avontuur, O.J. Bakker, R. Balm, W.B. Barendregt, J.A. Bekken, M.H. Bender, B.L. Bendermacher, M. van den Berg, P. Berger, R.J. Beuk, J.D. Blankensteijn, R.J. Bleker, J.J. Blok, A.S. Bode, M.E. Bodegom, K.E. van der Bogt, A.P. Boll, M.H. Booster, B.L. Borger van der Burg, G.J. de Borst, W.T. Bos- van Rossum, J. Bosma, J.M. Botman, L.H. Bouwman, V. Brehm, M.T. de Bruijn, J.L. de Bruin, P. Brummel, J.P. van Brussel, S.E. Buijk, M.A. Buijs, M.G. Buimer, D.H. Burger, H.C. Buscher, E. Cancrinus, P.H. Castenmiller, G. Cazander, A.M. Coester, P.H. Cuypers, J.H. Daemen, I. Dawson, J.E. Dierikx, M.L. Dijkstra, J. Diks, M.K. Dinkelman, M. Dirven, D.E. Dolmans, R.C. van Doorn, L.M. van Dortmont, J.W. Drouven, M.M. van der Eb, D. Eefting, G.J. van Eijck, J.W. Elshof, B.H. Elsman, A. van der Elst, M.I. van Engeland, R.G. van Eps, M.J. Faber, W.M. de Fijter, B. Fioole, T.M. Fokkema, F.A. Frans, W.M. Fritschy, P.H. Fung Kon Jin, R.H. Geelkerken, W.B. van Gent, G.J. Glade, B. Govaert, R.P. Groenendijk, H.G. de Groot, R.F. van den Haak, E.F. de Haan, G.F. Hajer, J.F. Hamming, E.S. van Hattum, C.E. Hazenberg, P.P. Hedeman Joosten, J.N. Helleman, L.G. van der Hem, J.M. Hendriks, J.A. van Herwaarden, J.M. Heyligers, J.W. Hinnen, R.J. Hissink, G.H. Ho, P.T. den Hoed, M.T. Hoedt, F. van Hoek, R. Hoencamp, W.H. Hoffmann, W. Hogendoorn, A.W. Hoksbergen, E.J. Hollander, M. Hommes, C.J. Hopmans, L.C. Huisman, R.G. Hulsebos, K.M. Huntjens, M.M. Idu, M.J. Jacobs, M.F. van der Jagt, J.R. Jansbeken, R.J. Janssen, H.H. Jiang, S.C. de Jong, T.A. Jongbloed-Winkel, V. Jongkind, M.R. Kapma, B.P. Keller, A. Khodadade Jahrome, J.K. Kievit, P.L. Klemm, P. Klinkert, N.A. Koedam, M.J. Koelemaij, J.L. Kolkert, G.G. Koning, O.H. Koning, R. Konings, A.G. Krasznai, R.M. Krol, R.H. Kropman, R.R. Kruse, L. van der Laan, M.J. van der Laan, J.H. van Laanen, G.W. van Lammeren, D.A. Lamprou, J.H. Lardenoye, G.J. Lauret, B.J. Leenders, D.A. Legemate, V.J. Leijdekkers, M.S. Lemson, M.M. Lensvelt, M.A. Lijkwan, R.C. Lind, F.T. van der Linden, P.F. Liqui Lung, M.J. Loos, M.C. Loubert, K.M. van de Luijtgaarden, D.E. Mahmoud, C.G. Manshanden, E.C. Mattens, R. Meerwaldt, B.M. Mees, G.C. von Meijenfeldt, T.P. Menting, R. Metz, R.C. Minnee, J.C. de Mol van Otterloo, M.J. Molegraaf, Y.C. Montauban van Swijndregt, M.J. Morak, R.H. van de Mortel, W. Mulder, S.K. Nagesser, C.C. Naves, J.H. Nederhoed, A.M. Nevenzel-Putters, A.J. de Nie, D.H. Nieuwenhuis, J. Nieuwenhuizen, R.C. van Nieuwenhuizen, D. Nio, V.J. Noyez, A.P. Oomen, B.I. Oranen, J. Oskam, H.W. Palamba, A.G. Peppelenbosch, A.S. van Petersen, B.J. Petri, M.E. Pierie, A.J. Ploeg, R.A. Pol, E.D. Ponfoort, I.C. Post, P.P. Poyck, A. Prent, S. ten Raa, J.T. Raymakers, M. Reichart, B.L. Reichmann, M.M. Reijnen, J.A. de Ridder, A. Rijbroek, M.J. van Rijn, R.A. de Roo, E.V. Rouwet, B.R. Saleem, P.B. Salemans, M.R. van Sambeek, M.G. Samyn, H.P. van ’t Sant, J. van Schaik, P.M. van Schaik, D.M. Scharn, M.R. Scheltinga, A. Schepers, P.M. Schlejen, F.J. Schlosser, F.P. Schol, V.P. Scholtes, O. Schouten, M.A. Schreve, G.W. Schurink, C.J. Sikkink, A. te Slaa, H.J. Smeets, L. Smeets, R.R. Smeets, A.A. de Smet, P.C. Smit, T.M. Smits, M.G. Snoeijs, A.O. Sondakh, M.J. Speijers, T.J. van der Steenhoven, S.M. van Sterkenburg, D.A. Stigter, R.A. Stokmans, R.P. Strating, G.N. Stultiëns, J.E. Sybrandy, J.A. Teijink, B.J. Telgenkamp, M. Teraa, M.J. Testroote, T. Tha-In, R.M. The, W.J. Thijsse, I. Thomassen, I.F. Tielliu, R.B. van Tongeren, R.J. Toorop, E. Tournoij, M. Truijers, K. Türkcan, R.P. Tutein Nolthenius, Ç. Ünlü, R.H. Vaes, A.A. Vafi, A.C. Vahl, E.J. Veen, H.T. Veger, M.G. Veldman, S. Velthuis, H.J. Verhagen, B.A. Verhoeven, C.F. Vermeulen, E.G. Vermeulen, B.P. Vierhout, R.J. van der Vijver-Coppen, M.J. Visser, J.A. van der Vliet, C.J. Vlijmen - van Keulen, R. Voorhoeve, J.R. van der Vorst, A.W. Vos, B. de Vos, C.G. Vos, G.A. Vos, M.T. Voute, B.H. Vriens, P.W. Vriens, A.C. de Vries, D.K. de Vries, J.P. de Vries, M. de Vries, C. van der Waal, E.J. Waasdorp, B.M. Wallis de Vries, L.A. van Walraven, J.L. van Wanroij, M.C. Warlé, W. van de Water, V. van Weel, A.M. van Well, G.M. Welten, R.J. Welten, J.J. Wever, A.M. Wiersema, O.R. Wikkeling, W.I. Willaert, J. Wille, M.C. Willems, E.M. Willigendael, E.D. Wilschut, W. Wisselink, M.E. Witte, C.H. Wittens, C.Y. Wong, R. Wouda, O. Yazar, K.K. Yeung, C.J. Zeebregts, M.L. van Zeeland, Multi-Modality Medical Imaging, Surgery, ACS - Atherosclerosis & ischemic syndromes, APH - Methodology, APH - Quality of Care, RS: CAPHRI - R5 - Optimising Patient Care, and Epidemiologie
- Subjects
Male ,Time Factors ,medicine.medical_treatment ,Vascular damage Radboud Institute for Health Sciences [Radboudumc 16] ,UT-Hybrid-D ,030204 cardiovascular system & hematology ,Logistic regression ,Endovascular aneurysm repair ,030218 nuclear medicine & medical imaging ,law.invention ,Postoperative Complications ,0302 clinical medicine ,Randomized controlled trial ,Risk Factors ,law ,80 and over ,Hospital Mortality ,Prospective Studies ,Prospective cohort study ,Netherlands ,Aged, 80 and over ,OUTCOMES ,Medical Audit ,education.field_of_study ,Endovascular Procedures ,Confounding ,Absolute risk reduction ,General Medicine ,EDITORS CHOICE ,Aortic Aneurysm ,Treatment Outcome ,OPEN SURGERY ,TRIAL ,Female ,Cardiology and Cardiovascular Medicine ,medicine.medical_specialty ,Aortic Rupture ,Clinical Decision-Making ,Population ,Abdominal/diagnostic imaging ,Postoperative Complications/mortality ,Risk Assessment ,Blood Vessel Prosthesis Implantation ,03 medical and health sciences ,medicine ,Humans ,Endovascular Procedures/adverse effects ,Blood Vessel Prosthesis Implantation/adverse effects ,education ,Aged ,business.industry ,MORTALITY ,ENDOVASCULAR REPAIR ,Surgery ,Aortic Rupture/diagnostic imaging ,Propensity score matching ,business ,Aortic Aneurysm, Abdominal/diagnostic imaging ,Aortic Aneurysm, Abdominal - Abstract
Contains fulltext : 229914.pdf (Publisher’s version ) (Open Access) BACKGROUND: While several observational studies suggested a lower postoperative mortality after minimal invasive endovascular aneurysm repair (EVAR) in patients with a ruptured abdominal aortic aneurysm (RAAA) compared to conventional open surgical repair (OSR), landmark randomized controlled trials have not been able to prove the superiority of EVAR over OSR. Randomized controlled trials contain a selected, homogeneous population, influencing external validity. Observational studies are biased and adjustment of confounders can be incomplete. Instrumental variable (IV) analysis (pseudorandomization) may help to answer the question if patients with an RAAA have lower postoperative mortality when undergoing EVAR compared to OSR. METHODS: This is an observational study including all patients with an RAAA, registered in the Dutch Surgical Aneurysm Audit between 2013 and 2017. The risk difference (RD) in postoperative mortality (30 days/in-hospital) between patients undergoing EVAR and OSR was estimated, in which adjustment for confounding was performed in 3 ways: linear model adjusted for observed confounders, propensity score model (multivariable logistic regression analysis), and IV analysis (two-stage least square regression), adjusting for observed and unobserved confounders, with the variation in percentage of EVAR per hospital as the IV instrument. RESULTS: 2419 patients with an RAAA (1489 OSR and 930 EVAR) were included. Unadjusted postoperative mortality was 34.9% after OSR and 22.6% after EVAR (RD 12.3%, 95% CI 8.5-16%). The RD adjusted for observed confounders using linear regression analysis and propensity score analysis was, respectively, 12.3% (95% CI 9.6-16.7%) and 13.2% (95%CI 9.3-17.1%) in favor of EVAR. Using IV analysis, adjusting for observed and unobserved confounders, RD was 8.9% (95% CI -1.1-18.9%) in favor of EVAR. CONCLUSIONS: Adjusting for observed confounders, patients with an RAAA undergoing EVAR had a significant better survival than OSR in a consecutive large cohort. Adjustment for unobserved confounders resulted in a clinical relevant RD. An "EVAR preference strategy" in patients with an RAAA could result in lower postoperative mortality.
- Published
- 2020
18. Vascular access training for REBOA placement: a feasibility study in a live tissue-simulator hybrid porcine model
- Author
-
Mark W. Bowyer, R. Hoencamp, Jaap F. Hamming, Tal M. Hörer, Boudewijn L S Borger van der Burg, T T C F van Dongen, D. Eefting, and Joseph J. DuBose
- Subjects
medicine.medical_specialty ,Percutaneous ,Swine ,Anatomical structures ,education ,Vascular access ,03 medical and health sciences ,0302 clinical medicine ,Surgical anatomy ,Medicine ,Animals ,Humans ,In patient ,030212 general & internal medicine ,Technical skills ,Femoral region ,business.industry ,Endovascular Procedures ,Models, Cardiovascular ,030208 emergency & critical care medicine ,General Medicine ,Balloon Occlusion ,Training methods ,Physical therapy ,Feasibility Studies ,business - Abstract
BackgroundThe use of resuscitative endovascular balloon occlusion of the aorta (REBOA) in patients with severe haemorrhagic shock is increasing. Obtaining vascular access is a necessary prerequisite for REBOA placement in these situations.MethodsDuring the EVTM workshop (September 2017, Örebro, Sweden), 21 individuals participated in this study, 16 participants and five instructors. A formalised curriculum was constructed including basic anatomy of the femoral region and basic training in access materials for REBOA placement in zone 1. Key skills: (1) preparation of endovascular toolkit, (2) achieving vascular access in the model and (3) bleeding control with REBOA. Scoring ranged from 0 to 5 for non-anatomical skills. Identification of anatomical structures was either sufficient (score=1) or insufficient (score=0). Five consultants performed a second identical procedure as a post test.ResultsConsultants had significantly better overall technical skills in comparison with residents (p=0.005), while understanding of surgical anatomy showed no difference. Procedure times differed significantly (pConclusionThis comprehensive training model using a live tissue-simulator hybrid porcine model can be used for femoral access and REBOA placement training in medical personnel with different prior training levels. Higher levels of training are associated with faster procedure times. Further research in open and percutaneous access training is necessary to simulate real-life situations. This training method can be used in a multistep training programme, in combination with realistic moulage and perfused cadaver models.
- Published
- 2019
19. Veno arterial-extra corporal membrane oxygenation for the treatment of cardiac failure in patients with infective endocarditis
- Author
-
Frank D. Eefting, Floris S. van den Brink, Jurriën M. ten Berg, Patrick Klein, Carlo Zivelonghi, Frans G.J. Waanders, Rob van Tooren, Erik Scholten, and Uday Sonker
- Subjects
Adult ,Male ,medicine.medical_specialty ,Bentall procedure ,030204 cardiovascular system & hematology ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Extracorporeal Membrane Oxygenation ,law ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Medical history ,030212 general & internal medicine ,Oxygenator ,Aged ,Advanced and Specialized Nursing ,Heart Failure ,Endocarditis ,business.industry ,General Medicine ,Middle Aged ,medicine.disease ,Cannula ,Intensive care unit ,Surgery ,Cardiac surgery ,Infective endocarditis ,Concomitant ,Female ,Cardiology and Cardiovascular Medicine ,business ,Safety Research - Abstract
Introduction:Surgery for infective endocarditis imposes great challenges in post-operative circulatory and pulmonary support but the role of veno-arterial extra-corporal membrane oxygenation in this respect is unclear.Methods:All patients undergoing veno-arterial extra-corporal membrane oxygenation after infective endocarditis surgery were analysed for age, gender, medical history, microorganisms, clinical outcome, complications and surgical procedure.Results:Between 2012 and 2016, 13 patients received veno-arterial extra-corporal membrane oxygenation following infective endocarditis surgery. The median age was 62 years (33-73) and 8/13 were male. Previous cardiac surgery was present in nine patients. Surgery for infective endocarditis consisted of a Bentall procedure in 10 patients, 2 of which received concomitant mitral valve surgery and 2 received concomitant coronary artery bypass graft. Valvular surgery alone was performed in three patients. Mortality on veno-arterial extra-corporal membrane oxygenation was 62% (8/13). Mortality during intensive care unit stay was 77% (10/13). Survival to discharge was 23% (3/13). One patient reached the 1 year survival point. Two patients who survived to discharge have not yet reached the 1 year survival point. Patient-related complications occurred in 54% (7/13) of patients and consisted of haemorrhage at the cannula site in four patients, leg ischaemia in one patient, haemorrhage at another site in one patient and infection of the cannula in one patient. Extra-corporal membrane oxygenation hardware-related complications occurred in one case consisting of clot formation in the oxygenator.Conclusion:Veno-arterial extra-corporal membrane oxygenation in post-cardiotomy patients who were operated on for infective endocarditis is feasible, but outcome is poor.
- Published
- 2019
20. Impact of mitral valve treatment choice on mortality according to aetiology
- Author
-
Benno J. Rensing, Ben J L Van den Branden, Martin J. Swaans, Frank D. Eefting, Juliette Velu, Remco A. J. Schurer, Jan Van der Heyden, Friso Kortlandt, Jan Baan, Berto J. Bouma, Johannes C. Kelder, Faculteit Medische Wetenschappen/UMCG, Graduate School, Cardiology, ACS - Pulmonary hypertension & thrombosis, ACS - Heart failure & arrhythmias, and APH - Aging & Later Life
- Subjects
medicine.medical_specialty ,Percutaneous ,medicine.medical_treatment ,030204 cardiovascular system & hematology ,REGURGITATION ,THERAPY ,03 medical and health sciences ,mitral valve repair ,0302 clinical medicine ,Mitral valve ,death ,medicine ,Humans ,030212 general & internal medicine ,Proportional Hazards Models ,Heart Valve Prosthesis Implantation ,REPAIR ,Mitral valve repair ,Mitral regurgitation ,business.industry ,Proportional hazards model ,MitraClip ,Patient Selection ,Hazard ratio ,Mitral Valve Insufficiency ,Confidence interval ,Surgery ,medicine.anatomical_structure ,Treatment Outcome ,clinical research ,Mitral Valve ,mitral regurgitation ,Cardiology and Cardiovascular Medicine ,business - Abstract
AIMS: Treatment strategies of high-risk patients with mitral regurgitation (MR) differ between disease based on functional and disease based on degenerative origin. In the present study, we aimed to evaluate the effect of surgical, percutaneous, or conservative treatment of MR according to MV mechanism, for high-risk patients. METHODS AND RESULTS: Survival outcomes of MitraClip, surgical, or conservative strategies were compared for 688 high-risk patients with functional MR and 275 with degenerative MR. Cox regression and propensity analyses were used to correct for differences in baseline characteristics. For functional MR, conservative treatment proved to have a higher mortality hazard when compared to MitraClip treatment (hazard ratio [HR] 1.79, 95% confidence interval [CI]: 1.34 to 2.39, p
- Published
- 2019
21. Transcatheter Tricuspid Valve Interventions: An Emerging Field
- Author
-
Livia L. Gheorghe, Jan Van der Heyden, Bushra S. Rana, Frank D. Eefting, Benno J. Rensing, Martin J. Swaans, and Martijn C. Post
- Subjects
medicine.medical_specialty ,Cardiac Catheterization ,Percutaneous ,Psychological intervention ,Tricuspid valve replacement ,Review ,030204 cardiovascular system & hematology ,Functional tricuspid regurgitation ,03 medical and health sciences ,0302 clinical medicine ,Tricuspid repair ,medicine ,Journal Article ,Humans ,High surgical risk ,030212 general & internal medicine ,Intensive care medicine ,Heart Valve Prosthesis Implantation ,Tricuspid valve ,High risk patients ,Transcatheter tricuspid valve interventions ,business.industry ,High-risk patients ,Tricuspid valve implantation ,Tricuspid Valve Insufficiency ,Cardiac surgery ,medicine.anatomical_structure ,Treatment Outcome ,Tricuspid Valve ,business ,Cardiology and Cardiovascular Medicine ,Cardiac imaging - Abstract
PURPOSE OF REVIEW: This review aims to provide an updated overview and a clinical perspective on novel transcatheter tricuspid valve interventions (TTVI), highlighting potential challenges and future directions. RECENT FINDINGS: Severe tricuspid regurgitation (TR) is a predictor of mortality. However, a sizeable number of patients remain untreated until the end-stage when cardiac surgery presents a prohibitive risk. The emergent need in finding a treatment for patients with TR, deemed for surgery options, has encouraged the development of TTVI. These procedures mimic classical surgery techniques and are mainly divided in four categories: annuloplasty and coaptation devices, edge-to-edge techniques and transcatheter tricuspid valve replacement. Early studies showed promising results, but long-term follow-up data are not available. For patients with severe TR and high surgical risk, several percutaneous options are available. However, these therapies are in a growing phase and bigger studies and long term follow-up are needed to prove their efficacy.
- Published
- 2019
22. Hartmann's procedure versus sigmoidectomy with primary anastomosis for perforated diverticulitis with purulent or faecal peritonitis (LADIES): a multicentre, parallel-group, randomised, open-label, superiority trial
- Author
-
Daniël P V Lambrichts, Sandra Vennix, Gijsbert D Musters, Irene M Mulder, Hilko A Swank, Anton G M Hoofwijk, Eric H J Belgers, Hein B A C Stockmann, Quirijn A J Eijsbouts, Michael F Gerhards, Bart A van Wagensveld, Anna A W van Geloven, Rogier M P H Crolla, Simon W Nienhuijs, Marc J P M Govaert, Salomone di Saverio, André J L D'Hoore, Esther C J Consten, Wilhelmina M U van Grevenstein, Robert E G J M Pierik, Philip M Kruyt, Joost A B van der Hoeven, Willem H Steup, Fausto Catena, Joop L M Konsten, Jefrey Vermeulen, Susan van Dieren, Willem A Bemelman, Johan F Lange, WC Hop, BC Opmeer, JB Reitsma, RA Scholte, EWH Waltmann, DA Legemate, JF Bartelsman, DW Meijer, Ç Ünlü, AB Kluit, Y El-Massoudi, RJCLM Vuylsteke, PJ Tanis, R Matthijsen, SW Polle, SM Lagarde, SS Gisbertz, O Wijers, JDW van der Bilt, MA Boermeester, R Blom, JAH Gooszen, MHF Schreinemacher, T van der Zande, MMN Leeuwenburgh, SAL Bartels, WLEM Hesp, L Koet, GP van der Schelling, E van Dessel, MLP van Zeeland, MMA Lensvelt, H Nijhof, S Verest, M Buijs, JH Wijsman, LPS Stassen, M Klinkert, MFG de Maat, G Sellenraad, J Jeekel, GJ Kleinrensink, T Tha-In, WN Nijboer, MJ Boom, PCM Verbeek, C Sietses, MWJ Stommel, PJ van Huijstee, JWS Merkus, D Eefting, JSD Mieog, D van Geldere, GA Patijn, M de Vries, M Boskamp, A Bentohami, TS Bijlsma, N de Korte, D Nio, H Rijna, J Luttikhold, MH van Gool, JF Fekkes, GJM Akkersdijk, G Heuff, EH Jutte, BA Kortmann, JM Werkman, W Laméris, L Rietbergen, P Frankenmolen, WA Draaisma, MAW Stam, MS Verweij, TM Karsten, LC de Nes, S Fortuin, SM de Castro, A Doeksen, MP Simons, GI Koffeman, EP Steller, JB Tuynman, P Boele van Hensbroek, M Mok, SR van Diepen, KWE Hulsewé, J Melenhorst, JHMB Stoot, S Fransen, MN Sosef, J van Bastelaar, YLJ Vissers, TPD Douchy, CE Christiaansen, R Smeenk, AM Pijnenburg, V Tanaydin, HTC Veger, SHEM Clermonts, M Al-Taher, EJR de Graaf, AG Menon, M Vermaas, HA Cense, E Jutte, MJ Wiezer, AB Smits, M Westerterp, HA Marsman, ER Hendriks, O van Ruler, EJC Vriens, JM Vogten, CC van Rossem, D Ohanis, E Tanis, J van Grinsven, JK Maring, J Heisterkamp, MGH Besselink, IHM Borel Rinkes, IQ Molenaar, JJA Joosten, V Jongkind, GMP Diepenhorst, MC Boute, M Smeenge, K Nielsen, JJ Harlaar, MDP Luyer, G van Montfort, JF Smulders, F Daams, E van Haren, GAP Nieuwenhuijzen, GJ Lauret, ITA Pereboom, RA Stokmans, A Birindelli, E Bianchi, S Pellegrini, I Terrasson, A Wolthuis, A de Buck van Overstraeten, S Nijs, Surgery, Radiology and nuclear medicine, Pediatrics, Public and occupational health, AGEM - Re-generation and cancer of the digestive system, ACS - Diabetes & metabolism, ACS - Microcirculation, ACS - Atherosclerosis & ischemic syndromes, Robotics and image-guided minimally-invasive surgery (ROBOTICS), AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, APH - Methodology, AGEM - Digestive immunity, Clinical Research Unit, and AII - Infectious diseases
- Subjects
Male ,REVERSAL ,SURGERY ,medicine.medical_treatment ,DISEASE ,Diverticulitis, Colonic ,law.invention ,Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14] ,0302 clinical medicine ,Postoperative Complications ,Randomized controlled trial ,Sigmoidectomy ,law ,QUALITY-OF-LIFE ,Surgical ,Colostomy ,Clinical endpoint ,Medicine ,education.field_of_study ,Proctectomy ,Ileostomy ,Anastomosis, Surgical ,Gastroenterology ,Diverticulitis ,Middle Aged ,Treatment Outcome ,030220 oncology & carcinogenesis ,030211 gastroenterology & hepatology ,Female ,Life Sciences & Biomedicine ,medicine.medical_specialty ,GENERALIZED PERITONITIS ,RESECTION ,Anastomosis ,Colon ,Population ,Sigmoid ,Peritonitis ,CLINICAL-TRIAL ,03 medical and health sciences ,Colonic ,Colon, Sigmoid ,Journal Article ,MANAGEMENT ,Humans ,education ,Aged ,Science & Technology ,COLONIC DIVERTICULITIS ,Hepatology ,Intestinal Perforation ,Rectum ,Gastroenterology & Hepatology ,business.industry ,medicine.disease ,Surgery ,business - Abstract
BACKGROUND: Previous studies have suggested that sigmoidectomy with primary anastomosis is superior to Hartmann's procedure. The likelihood of stoma reversal after primary anastomosis has been reported to be higher and reversal seems to be associated with lower morbidity and mortality. Although promising, results from these previous studies remain uncertain because of potential selection bias. Therefore, this study aimed to assess outcomes after Hartmann's procedure versus sigmoidectomy with primary anastomosis, with or without defunctioning ileostomy, for perforated diverticulitis with purulent or faecal peritonitis (Hinchey III or IV disease) in a randomised trial. METHODS: A multicentre, randomised, open-label, superiority trial was done in eight academic hospitals and 34 teaching hospitals in Belgium, Italy, and the Netherlands. Patients aged between 18 and 85 years who presented with clinical signs of general peritonitis and suspected perforated diverticulitis were eligible for inclusion if plain abdominal radiography or CT scan showed diffuse free air or fluid. Patients with Hinchey I or II diverticulitis were not eligible for inclusion. Patients were allocated (1:1) to Hartmann's procedure or sigmoidectomy with primary anastomosis, with or without defunctioning ileostomy. Patients were enrolled by the surgeon or surgical resident involved, and secure online randomisation software was used in the operating room or by the trial coordinator on the phone. Random and concealed block sizes of two, four, or six were used, and randomisation was stratified by age (
- Published
- 2019
- Full Text
- View/download PDF
23. Failure to Rescue - a Closer Look at Mortality Rates Has No Added Value for Hospital Comparisons but Is Useful for Team Quality Assessment in Abdominal Aortic Aneurysm Surgery in The Netherlands
- Author
-
Niki Lijftogt, Eleonora G. Karthaus, Anco Vahl, Erik W. van Zwet, Esmee M. van der Willik, Robertus A.E.M. Tollenaar, Jaap F. Hamming, Michel W.J.M. Wouters, L.H. Van den Akker, P.J. Van den Akker, G.J. Akkersdijk, G.P. Akkersdijk, W.L. Akkersdijk, M.G. van Andringa de Kempenaer, C.H. Arts, J.A. Avontuur, J.G. Baal, O.J. Bakker, R. Balm, W.B. Barendregt, M.H. Bender, B.L. Bendermacher, M. van den Berg, P. Berger, R.J. Beuk, J.D. Blankensteijn, R.J. Bleker, J.H. Bockel, M.E. Bodegom, K.E. Bogt, A.P. Boll, M.H. Booster, B.L. Borger van der Burg, G.J. de Borst, W.T. Bos-van Rossum, J. Bosma, J.M. Botman, L.H. Bouwman, J.C. Breek, V. Brehm, M.J. Brinckman, T.H. van den Broek, H.L. Brom, M.T. de Bruijn, J.L. de Bruin, P. Brummel, J.P. van Brussel, S.E. Buijk, M.G. Buimer, D.H. Burger, H.C. Buscher, G. den Butter, E. Cancrinus, P.H. Castenmiller, G. Cazander, H.M. Coveliers, P.H. Cuypers, J.H. Daemen, I. Dawson, A.F. Derom, A.R. Dijkema, J. Diks, M.K. Dinkelman, M. Dirven, D.E. Dolmans, R.C. van Doorn, L.M. van Dortmont, M.M. van der Eb, D. Eefting, G.J. van Eijck, J.W. Elshof, B.H. Elsman, A. van der Elst, M.I. van Engeland, R.G. van Eps, M.J. Faber, W.M. de Fijter, B. Fioole, W.M. Fritschy, R.H. Geelkerken, W.B. van Gent, G.J. Glade, B. Govaert, R.P. Groenendijk, H.G. de Groot, R.F. van den Haak, E.F. de Haan, G.F. Hajer, J.F. Hamming, E.S. van Hattum, C.E. Hazenberg, P.P. Hedeman Joosten, J.N. Helleman, L.G. van der Hem, J.M. Hendriks, J.A. van Herwaarden, J.M. Heyligers, J.W. Hinnen, R.J. Hissink, G.H. Ho, P.T. den Hoed, M.T. Hoedt, F. van Hoek, R. Hoencamp, W.H. Hoffmann, A.W. Hoksbergen, E.J. Hollander, L.C. Huisman, R.G. Hulsebos, K.M. Huntjens, M.M. Idu, M.J. Jacobs, M.F. van der Jagt, J.R. Jansbeken, R.J. Janssen, H.H. Jiang, S.C. de Jong, V. Jongkind, M.R. Kapma, B.P. Keller, A. Khodadade Jahrome, J.K. Kievit, P.L. Klemm, P. Klinkert, B. Knippenberg, N.A. Koedam, M.J. Koelemaij, J.L. Kolkert, G.G. Koning, O.H. Koning, A.G. Krasznai, R.M. Krol, R.H. Kropman, R.R. Kruse, L. van der Laan, M.J. van der Laan, J.H. van Laanen, J.H. Lardenoye, J.A. Lawson, D.A. Legemate, V.J. Leijdekkers, M.S. Lemson, M.M. Lensvelt, M.A. Lijkwan, R.C. Lind, F.T. van der Linden, P.F. Liqui Lung, M.J. Loos, M.C. Loubert, D.E. Mahmoud, C.G. Manshanden, E.C. Mattens, R. Meerwaldt, B.M. Mees, R. Metz, R.C. Minnee, J.C. de Mol van Otterloo, F.L. Moll, Y.C. Montauban van Swijndregt, M.J. Morak, R.H. van de Mortel, W. Mulder, S.K. Nagesser, C.C. Naves, J.H. Nederhoed, A.M. Nevenzel-Putters, A.J. de Nie, D.H. Nieuwenhuis, J. Nieuwenhuizen, R.C. van Nieuwenhuizen, D. Nio, A.P. Oomen, B.I. Oranen, J. Oskam, H.W. Palamba, A.G. Peppelenbosch, A.S. van Petersen, T.F. Peterson, B.J. Petri, M.E. Pierie, A.J. Ploeg, R.A. Pol, E.D. Ponfoort, P.P. Poyck, A. Prent, S. ten Raa, J.T. Raymakers, M. Reichart, B.L. Reichmann, M.M. Reijnen, A. Rijbroek, M.J. van Rijn, R.A. de Roo, E.V. Rouwet, C.G. Rupert, B.R. Saleem, M.R. van Sambeek, M.G. Samyn, H.P. van ’t Sant, J. van Schaik, P.M. van Schaik, D.M. Scharn, M.R. Scheltinga, A. Schepers, P.M. Schlejen, F.J. Schlosser, F.P. Schol, O. Schouten, M.H. Schreinemacher, M.A. Schreve, G.W. Schurink, C.J. Sikkink, M.P. Siroen, A. te Slaa, H.J. Smeets, L. Smeets, A.A. de Smet, P. de Smit, P.C. Smit, T.M. Smits, M.G. Snoeijs, A.O. Sondakh, T.J. van der Steenhoven, S.M. van Sterkenburg, D.A. Stigter, H. Stigter, R.P. Strating, G.N. Stultiëns, J.E. Sybrandy, J.A. Teijink, B.J. Telgenkamp, M.J. Testroote, R.M. The, W.J. Thijsse, I.F. Tielliu, R.B. van Tongeren, R.J. Toorop, J.H. Tordoir, E. Tournoij, M. Truijers, K. Türkcan, R.P. Tutein Nolthenius, Ç. Ünlü, A.A. Vafi, A.C. Vahl, E.J. Veen, H.T. Veger, M.G. Veldman, H.J. Verhagen, B.A. Verhoeven, C.F. Vermeulen, E.G. Vermeulen, B.P. Vierhout, M.J. Visser, J.A. van der Vliet, C.J. Vlijmen-van Keulen, H.G. Voesten, R. Voorhoeve, A.W. Vos, B. de Vos, G.A. Vos, B.H. Vriens, P.W. Vriens, A.C. de Vries, J.P. de Vries, M. de Vries, C. van der Waal, E.J. Waasdorp, B.M. Wallis de Vries, L.A. van Walraven, J.L. van Wanroij, M.C. Warlé, V. van Weel, A.M. van Well, G.M. Welten, R.J. Welten, J.J. Wever, A.M. Wiersema, O.R. Wikkeling, W.I. Willaert, J. Wille, M.C. Willems, E.M. Willigendael, W. Wisselink, M.E. Witte, C.H. Wittens, I.C. Wolf-de Jonge, O. Yazar, C.J. Zeebregts, M.L. van Zeeland, RS: CAPHRI - R5 - Optimising Patient Care, Epidemiologie, Surgery, Pediatrics, ACS - Atherosclerosis & ischemic syndromes, Pathology, Dermatology, ACS - Microcirculation, AII - Inflammatory diseases, and AGEM - Digestive immunity
- Subjects
Clinical audit ,medicine.medical_specialty ,Funnel plot ,TO-RESCUE ,Time Factors ,Failure to rescue ,Vascular damage Radboud Institute for Health Sciences [Radboudumc 16] ,MODELS ,030204 cardiovascular system & hematology ,030230 surgery ,PREVENTABILITY ,03 medical and health sciences ,Postoperative Complications ,0302 clinical medicine ,Aneurysm ,medicine ,Humans ,Hospital Mortality ,SURGICAL COLORECTAL AUDIT ,Netherlands ,TRAUMA ,REPAIR ,RISK ,Surgical outcome ,OUTCOMES ,medicine.diagnostic_test ,business.industry ,Mortality rate ,Endovascular Procedures ,Glasgow Coma Scale ,CARE ,medicine.disease ,Quality Improvement ,CANCER ,Hospitals ,Abdominal aortic aneurysm ,Surgery ,Composite outcome measures ,Elective Surgical Procedures ,Cardiology and Cardiovascular Medicine ,business ,Electrocardiography ,Aortic Aneurysm, Abdominal - Abstract
Objectives: Failure to rescue (FTR) is a composite quality indicator, defined as the proportion of deceased patients following major complications. The aims of this study were to compare FTR with mortality for hospital comparisons in abdominal aortic aneurysm (AAA) surgery in The Netherlands and investigate hospital volume and associated factors.Methods: Patients prospectively registered between 2013 and 2015 in the Dutch Surgical Aneurysm Audit (DSAA) were analysed. FTR was analysed for AAA patients and subgroups elective (EAAA) and acute (AAAA; symptomatic or ruptured) aneurysms. Variables and hospital volume were analysed by uni- and multivariable regression analysis. Adjusted hospital comparisons for mortality, major complications, and FTR were presented in funnel plots. Isomortality lines were constructed when presenting FTR and major complication rates.Results: A total of 9258 patients were analysed in 61 hospitals: 7149 EAAA patients (77.2%) and 2109 AAAA patients (22.8%). There were 2785 (30.1%) patients with complications (unadjusted range 5-65% per hospital): 2161 (77.6%) with major and 624 (28.4%) patients with minor complications. Overall mortality was 6.6% (adjusted range 0-16% per hospital) and FTR was 28.4% (n = 613) (adjusted range 0-60% per hospital). Glasgow Coma Scale, age, pulse, creatinine, electrocardiography, and operative setting were independently associated with FTR. Hospital volume was not associated with FTR. In AAAA patients hospital volume was significantly associated with a lower adjusted major complication and mortality rate (OR 0.62, 95% CI 0.49-0.78; and 0.64, 95% CI 0.48-0.87). Four hospitals had a significant lower adjusted FTR with different major complication rates on different isomortality lines.Conclusions: There was more variation in FTR than in mortality between hospitals. FTR identified the same best performing hospitals as for mortality and therefore was of limited additional value in measuring quality of care for AAA surgery. FTR can be used for internal quality improvement with major complications in funnel plots and diagrams with isomortality lines. (C) 2018 European Society for Vascular Surgery. Published by Elsevier B.V. All rights reserved.
- Published
- 2018
- Full Text
- View/download PDF
24. P1688Natural history of coronary lesions in the distal segment of total occlusions after successful percutaneous recanalization
- Author
-
J P S Henriques, Pierfrancesco Agostoni, Giulia Vinco, Carlo Zivelonghi, J. M. ten Berg, Benno J. Rensing, Frank D. Eefting, J.P. van Kuijk, Flavio Ribichini, Giovanni Benfari, J.A.S. Van Der Heyden, Koen Teeuwen, and M. J. Suttorp
- Subjects
medicine.medical_specialty ,Percutaneous ,business.industry ,medicine ,Distal segment ,Cardiology and Cardiovascular Medicine ,business ,Surgery - Published
- 2018
- Full Text
- View/download PDF
25. Long-term survival and preprocedural predictors of mortality in high surgical risk patients undergoing percutaneous mitral valve repair
- Author
-
Frank D. Eefting, Martin J. Swaans, Friso Kortlandt, Andreas S. Triantafyllis, A.L.M. Bakker, Martijn C. Post, Benno W.J.M. Rensing, and Jan Van der Heyden
- Subjects
Mitral regurgitation ,medicine.medical_specialty ,Univariate analysis ,Percutaneous ,business.industry ,Proportional hazards model ,MitraClip ,medicine.medical_treatment ,General Medicine ,030204 cardiovascular system & hematology ,Surgery ,03 medical and health sciences ,0302 clinical medicine ,medicine.anatomical_structure ,Mitral valve ,Internal medicine ,medicine ,Cardiology ,Radiology, Nuclear Medicine and imaging ,030212 general & internal medicine ,Cardiology and Cardiovascular Medicine ,business ,Percutaneous Mitral Valve Repair ,Cardiac catheterization - Abstract
Objectives To evaluate long-term survival in high surgical risk patients undergoing percutaneous mitral valve repair (MVR) using the MitraClip® system and to identify preprocedural predictors of long-term mortality. Background Data for long-term survival and preprocedural predictors of mortality after percutaneous MVR in high surgical risk patients are sporadic. Methods From January 2009 to April 2013, 136 consecutive high surgical risk patients, with symptomatic moderate-to-severe or severe mitral regurgitation (MR), underwent percutaneous MVR using the MitraClip system. Cardiac and overall survival was determined at one and 2 years postprocedure. Univariate and multivariate analysis was performed to identify preprocedural predictors of long-term mortality. Results One year postprocedure, cardiac and overall survival was 86.7% and 84.6%, respectively and at 2 years cardiac and overall survival was 77.7% and 74.8%, respectively. In univariate analysis advanced age, lower body mass index, impaired renal function, elevated levels of log-N-terminal-pro-brain-natriuretic-peptide (log-NTproBNP), poor performance in functional tests (New York Heart Association (NYHA) class) and high logistic Euroscore (LES) and Society of Thoracic Surgeons (STS) score were identified as preprocedural predictors of long-term cardiac mortality. In multivariate analysis preoperative NYHA class III and IV, elevated levels of log-NTproBNP and advanced age predicted long-term cardiac mortality. Conclusions Percutaneous MVR using the MitraClip system has favorable long-term survival rates in high surgical risk patients. Preprocedural NYHA functional class III and IV, elevated log-NTproBNP levels and advanced age predict higher long-term cardiac mortality and should be considered during patient selection. © 2015 Wiley Periodicals, Inc.
- Published
- 2015
- Full Text
- View/download PDF
26. The Dutch Audit of Carotid Interventions: Transparency in Quality of Carotid Endarterectomy in Symptomatic Patients in the Netherlands
- Author
-
Eleonora G. Karthaus, Anco Vahl, Laurien S. Kuhrij, Bernard H.P. Elsman, Robert H. Geelkerken, Michel W.J.M. Wouters, Jaap F. Hamming, Gert J. de Borst, L.H. Van den Akker, P.J. Van den Akker, G.J. Akkersdijk, G.P. Akkersdijk, W.L. Akkersdijk, M.G. van Andringa de Kempenaer, C.H. Arts, J.A. Avontuur, J.G. Baal, O.J. Bakker, R. Balm, W.B. Barendregt, M.H. Bender, B.L. Bendermacher, M. van den Berg, P. Berger, R.J. Beuk, J.D. Blankensteijn, R.J. Bleker, J.H. Bockel, M.E. Bodegom, K.E. Bogt, A.P. Boll, M.H. Booster, B.L. Borger van der Burg, G.J. de Borst, W.T. Bos- van Rossum, J. Bosma, J.M. Botman, L.H. Bouwman, J.C. Breek, V. Brehm, M.J. Brinckman, T.H. van den Broek, H.L. Brom, M.T. de Bruijn, J.L. de Bruin, P. Brummel, J.P. van Brussel, S.E. Buijk, M.G. Buimer, D.H. Burger, H.C. Buscher, G. den Butter, E. Cancrinus, P.H. Castenmiller, G. Cazander, H.M. Coveliers, P.H. Cuypers, J.H. Daemen, I. Dawson, A.F. Derom, A.R. Dijkema, J. Diks, M.K. Dinkelman, M. Dirven, D.E. Dolmans, R.C. van Doorn, L.M. van Dortmont, M.M. van der Eb, D. Eefting, G.J. van Eijck, J.W. Elshof, B.H. Elsman, A. van der Elst, M.I. van Engeland, R.G. van Eps, M.J. Faber, W.M. de Fijter, B. Fioole, W.M. Fritschy, R.H. Geelkerken, W.B. van Gent, G.J. Glade, B. Govaert, R.P. Groenendijk, H.G. de Groot, R.F. van den Haak, E.F. de Haan, G.F. Hajer, J.F. Hamming, E.S. van Hattum, C.E. Hazenberg, P.P. Hedeman Joosten, J.N. Helleman, L.G. van der Hem, J.M. Hendriks, J.A. van Herwaarden, J.M. Heyligers, J.W. Hinnen, R.J. Hissink, G.H. Ho, P.T. den Hoed, M.T. Hoedt, F. van Hoek, R. Hoencamp, W.H. Hoffmann, A.W. Hoksbergen, E.J. Hollander, L.C. Huisman, R.G. Hulsebos, K.M. Huntjens, M.M. Idu, M.J. Jacobs, M.F. van der Jagt, J.R. Jansbeken, R.J. Janssen, H.H. Jiang, S.C. de Jong, V. Jongkind, M.R. Kapma, B.P. Keller, A. Khodadade Jahrome, J.K. Kievit, P.L. Klemm, P. Klinkert, B. Knippenberg, N.A. Koedam, M.J. Koelemaij, J.L. Kolkert, G.G. Koning, O.H. Koning, A.G. Krasznai, R.M. Krol, R.H. Kropman, R.R. Kruse, L. van der Laan, M.J. van der Laan, J.H. van Laanen, J.H. Lardenoye, J.A. Lawson, D.A. Legemate, V.J. Leijdekkers, M.S. Lemson, M.M. Lensvelt, M.A. Lijkwan, R.C. Lind, F.T. van der Linden, P.F. Liqui Lung, M.J. Loos, M.C. Loubert, D.E. Mahmoud, C.G. Manshanden, E.C. Mattens, R. Meerwaldt, B.M. Mees, R. Metz, R.C. Minnee, J.C. de Mol van Otterloo, F.L. Moll, Y.C. Montauban van Swijndregt, M.J. Morak, R.H. van de Mortel, W. Mulder, S.K. Nagesser, C.C. Naves, J.H. Nederhoed, A.M. Nevenzel-Putters, A.J. de Nie, D.H. Nieuwenhuis, J. Nieuwenhuizen, R.C. van Nieuwenhuizen, D. Nio, A.P. Oomen, B.I. Oranen, J. Oskam, H.W. Palamba, A.G. Peppelenbosch, A.S. van Petersen, T.F. Peterson, B.J. Petri, M.E. Pierie, A.J. Ploeg, R.A. Pol, E.D. Ponfoort, P.P. Poyck, A. Prent, S. ten Raa, J.T. Raymakers, M. Reichart, B.L. Reichmann, M.M. Reijnen, A. Rijbroek, M.J. van Rijn, R.A. de Roo, E.V. Rouwet, C.G. Rupert, B.R. Saleem, M.R. van Sambeek, M.G. Samyn, H.P. van 't Sant, J. van Schaik, P.M. van Schaik, D.M. Scharn, M.R. Scheltinga, A. Schepers, P.M. Schlejen, F.J. Schlosser, F.P. Schol, O. Schouten, M.H. Schreinemacher, M.A. Schreve, G.W. Schurink, C.J. Sikkink, M.P. Siroen, A. te Slaa, H.J. Smeets, L. Smeets, A.A. de Smet, P. de Smit, P.C. Smit, T.M. Smits, M.G. Snoeijs, A.O. Sondakh, T.J. van der Steenhoven, S.M. van Sterkenburg, D.A. Stigter, H. Stigter, R.P. Strating, D. Stultiëns, J.E. Sybrandy, J.A. Teijink, B.J. Telgenkamp, M.J. Testroote, R.M. The, W.J. Thijsse, I.F. Tielliu, R.B. van Tongeren, R.J. Toorop, J.H. Tordoir, E. Tournoij, M. Truijers, K. Türkcan, R.P. Tutein Nolthenius, Ç. Ünlü, A.A. Vafi, A.C. Vahl, E.J. Veen, H.T. Veger, M.G. Veldman, H.J. Verhagen, B.A. Verhoeven, C.F. Vermeulen, E.G. Vermeulen, B.P. Vierhout, M.J. Visser, J.A. van der Vliet, C.J. Vlijmen - van Keulen, H.G. Voesten, R. Voorhoeve, A.W. Vos, B. de Vos, G.A. Vos, B.H. Vriens, P.W. Vriens, A.C. de Vries, J.P. de Vries, M. de Vries, C. van der Waal, E.J. Waasdorp, B.M. Wallis de Vries, L.A. van Walraven, J.L. van Wanroij, M.C. Warlé, V. van Weel, A.M. van Well, G.M. Welten, R.J. Welten, J.J. Wever, A.M. Wiersema, O.R. Wikkeling, W.I. Willaert, J. Wille, M.C. Willems, E.M. Willigendael, W. Wisselink, M.E. Witte, C.H. Wittens, I.C. Wolf-de Jonge, O. Yazar, C.J. Zeebregts, M.L. van Zeeland, Jan-Willem Elshof, Martine C. Willems, Surgery, ACS - Atherosclerosis & ischemic syndromes, Pathology, Pediatrics, Dermatology, ACS - Microcirculation, AII - Inflammatory diseases, AGEM - Digestive immunity, RS: CAPHRI - R5 - Optimising Patient Care, Epidemiologie, ANS - Neurovascular Disorders, Graduate School, and Multi-Modality Medical Imaging
- Subjects
Male ,medicine.medical_specialty ,Patients ,medicine.medical_treatment ,Vascular damage Radboud Institute for Health Sciences [Radboudumc 16] ,Psychological intervention ,Carotid endarterectomy ,030204 cardiovascular system & hematology ,Revascularization ,Logistic regression ,STENOSIS ,Risk Assessment ,03 medical and health sciences ,0302 clinical medicine ,CEA ,National clinical audit ,Risk Factors ,medicine ,Humans ,Carotid Stenosis ,Hospital Mortality ,030212 general & internal medicine ,PREDICTORS ,Stroke ,Netherlands ,OUTCOMES ,COMPLICATIONS ,Endarterectomy, Carotid ,business.industry ,Mortality rate ,DEATH ,Quality of care ,Symptomatic carotid artery stenosis ,medicine.disease ,n/a OA procedure ,Stenosis ,TRIALS ,Treatment Outcome ,Cohort ,Emergency medicine ,REVASCULARIZATION ,Female ,Surgery ,Cardiology and Cardiovascular Medicine ,business - Abstract
Background: The Dutch Audit for Carotid Interventions (DACI) registers all patients undergoing interventions for carotid artery stenosis in the Netherlands. This study describes the design of the DACI and results of patients with a symptomatic stenosis undergoing carotid endarterectomy (CEA). It aimed to evaluate variation between hospitals in process of care and (adjusted) outcomes, as well as predictors of major stroke/death after CEA.Methods: All patients with a symptomatic stenosis, who underwent CEA and were registered in the DACI between 2014 and 2016 were included in this cohort. Descriptive analyses of patient characteristics, process of care, and outcomes were performed. Casemix adjusted hospital procedural outcomes as (30 day/in hospital) mortality, stroke/death, and major stroke/death, were compared with the national mean. A multivariable logistic regression model (backward elimination at p > 0.10) was used to identify predictors of major stroke/death.Results: A total of 6459 patients, registered by 52 hospitals, were included. The majority (4,832, 75%) were treated Conclusion: CEA in The Netherlands is associated with an overall low mortality and (major) stroke/death rate. Whereas the indicator time to intervention varied between hospitals, mortality and (major) stroke/death were not significantly distinctive enough to identify worse practices and therefore were unsuitable for hospital comparison in the Dutch setting. Additionally, predictors of major stroke/death at population level could be identified. (C) 2018 European Society for Vascular Surgery. Published by Elsevier B.V. All rights reserved.
- Published
- 2018
- Full Text
- View/download PDF
27. Survival after MitraClip Treatment Compared to Surgical and Conservative Treatment for High-Surgical-Risk Patients with Mitral Regurgitation
- Author
-
Marco C. Post, Berto J. Bouma, Jan Van der Heyden, Frank D. Eefting, Martin J. Swaans, Johannes C. Kelder, Ted Feldman, Pim van der Harst, Juliëtte F. Velu, Tom Hendriks, Benno J. Rensing, A.L.M. Bakker, Friso Kortlandt, Jan Baan, Ben J L Van den Branden, Remco A. J. Schurer, Cardiovascular Centre (CVC), Cardiology, ACS - Pulmonary hypertension & thrombosis, ACS - Heart failure & arrhythmias, and APH - Aging & Later Life
- Subjects
Male ,mitral valve ,medicine.medical_specialty ,Time Factors ,SURGERY ,conservative treatment ,VALVULAR HEART-DISEASE ,030204 cardiovascular system & hematology ,Prosthesis Design ,Risk Assessment ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Mitral valve ,medicine ,MANAGEMENT ,Humans ,High surgical risk ,030212 general & internal medicine ,uncertainty ,Aged ,Netherlands ,Retrospective Studies ,Aged, 80 and over ,Heart Valve Prosthesis Implantation ,Mitral regurgitation ,business.industry ,MitraClip ,MORTALITY ,valvular heart disease ,Hemodynamics ,Mitral Valve Insufficiency ,Recovery of Function ,Middle Aged ,medicine.disease ,Comorbidity ,Surgery ,Conservative treatment ,comorbidity ,Treatment Outcome ,medicine.anatomical_structure ,Heart Valve Prosthesis ,VALVE REPAIR ,REGISTRY ,Female ,prognosis ,Cardiology and Cardiovascular Medicine ,business ,SYSTEM - Abstract
Background— Survival outcome after MitraClip treatment, compared with surgical or conservative treatment, is not well defined. We examined survival after MitraClip treatment in a large multicenter real-life setting. Methods and Results— We retrospectively formed matched high-risk surgically and conservatively treated control cohorts to compare to a high-risk MitraClip cohort. One thousand thirty-six patients were included in 4 Dutch centers, of which 568 were treated with the MitraClip. The observed survival at 5-year follow-up in our MitraClip cohort was low (39.8%) but was comparable to our conservative cohort (40.5%). Observed 5-year survival for our surgical cohort was 76.3%. However, there were significant differences between the baseline characteristics of the 3 studied cohorts, with the MitraClip cohort having the highest comorbidity burden. After adjusting for baseline differences by using Cox regression, the MitraClip and surgical cohorts showed similar survival ratios (hazard ratio, 0.92; 95% confidence interval, 0.67–1.26; P =0.609), whereas both showed a lower mortality hazard when compared with conservative treatment (hazard ratio, 0.61; 95% confidence interval, 0.49–0.77; P P Conclusions— This matched analysis suggests a lower mortality hazard for MitraClip intervention in a high-risk population with symptomatic mitral regurgitation when compared with conservative management alone.
- Published
- 2018
28. Clinical Implications of Distal Vessel Stenosis After Successful Coronary Chronic Total Occlusion Recanalization
- Author
-
Koen Teeuwen, José P.S. Henriques, Jan G.P. Tijssen, Maarten J. Suttorp, Pierfrancesco Agostoni, Benno J. Rensing, Jan Peter van Kuijk, Jurriën M. ten Berg, Carlo Zivelonghi, Frank D. Eefting, Flavio Ribichini, Jan Van der Heyden, Giovanni Benfari, Floris S. van den Brink, Graduate School, ACS - Heart failure & arrhythmias, Cardiology, and ACS - Atherosclerosis & ischemic syndromes
- Subjects
Coronary angiography ,medicine.medical_specialty ,Treatment outcome ,030204 cardiovascular system & hematology ,Coronary Angiography ,Total occlusion ,Lesion ,03 medical and health sciences ,Percutaneous Coronary Intervention ,0302 clinical medicine ,Risk Factors ,Internal medicine ,Occlusion ,medicine ,Humans ,030212 general & internal medicine ,Coronary atherosclerosis ,Randomized Controlled Trials as Topic ,business.industry ,Coronary Stenosis ,Drug-Eluting Stents ,medicine.disease ,Stenosis ,Treatment Outcome ,Chronic disease ,Coronary Occlusion ,Chronic Disease ,Cardiology ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,business ,see www.pubmed.gov - Abstract
Chronic total occlusions (CTOs) represent the ultimate stage of coronary atherosclerosis, with commonly associated high plaque burden upstream and downstream of the occlusion itself. Physiological modifications in the vessel distal to the CTO lesion lead to negative vascular remodeling and plaque
- Published
- 2018
29. Increased incidence of infective endocarditis after the 2009 European Society of Cardiology guideline update: a nationwide study in the Netherlands
- Author
-
A. Jon Funke Kupper, Mark G. Hoogendijk, Martin J. Swaans, Frank D. Eefting, Bjorn Groenmeijer, Floris S. van den Brink, Arash Alipour, W. Jaarsma, Johannes C. Kelder, and Jurriën M. ten Berg
- Subjects
Adult ,Male ,medicine.medical_specialty ,Time Factors ,Cardiology ,030204 cardiovascular system & hematology ,Rate ratio ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Endocarditis ,Humans ,030212 general & internal medicine ,Registries ,Societies, Medical ,Aged ,Netherlands ,Retrospective Studies ,Aged, 80 and over ,business.industry ,Health Policy ,Incidence (epidemiology) ,Incidence ,Guideline ,Patient data ,Middle Aged ,medicine.disease ,Europe ,Trend analysis ,Infective endocarditis ,Practice Guidelines as Topic ,Observational study ,Female ,Cardiology and Cardiovascular Medicine ,business ,Follow-Up Studies - Abstract
Aims After the introduction of the European Society of Cardiology (ESC) guidelines on prevention, diagnosis, and treatment of infective endocarditis (IE) in 2009, prophylaxis for patients at risk became less strict. We hypothesize that there will be a rise in IE after the introduction of the guideline update. Methods and Results We performed a nationwide retrospective trend study using segmented regression analysis of the interrupted time series. The patient data were obtained via the national healthcare insurance database, which collects all the diagnoses nationwide. We compared the data before and after the introduction of the 2009 ESC guideline. Between 2005 and 2011, a total of 5213 patients were hospitalized with IE in the Netherlands. During this period, there was a significant increase in IE from 30.2 new cases per 1 000 000 in 2005 to 62.9 cases per 1 000 000 in 2011 (P < 0.001). In 2009, the incidence of IE increased significantly above the projected historical trend (rate ratio: 1.327, 95% CI: 1.205–1.462; P < 0.001). This coincides with the introduction of the 2009 ESC guideline. After the introduction of the ESC guideline, the streptococci-positive cultures increased significantly in the following years 2010–11 from 31.1 to 53.2% (P = 0.0031). Conclusion This observational study shows that there has been a steady increase in the IE incidence between 2005 and 2011. After the introduction of the 2009 ESC guidelines, the incidence increased more than expected from previous historical trends. Furthermore, there was a significant increase in streptococci-related IE cases.
- Published
- 2016
30. Mortality after percutaneous edge-to-edge mitral valve repair: a contemporary review
- Author
-
Marco C. Post, Friso Kortlandt, Benno J. Rensing, Frank D. Eefting, Jan Van der Heyden, Martin J. Swaans, and Thomas de Beenhouwer
- Subjects
medicine.medical_specialty ,Mitral regurgitation ,Mitral valve repair ,Percutaneous ,business.industry ,medicine.medical_treatment ,Treatment options ,Review Article ,030204 cardiovascular system & hematology ,law.invention ,Surgery ,03 medical and health sciences ,0302 clinical medicine ,medicine.anatomical_structure ,Randomized controlled trial ,law ,Internal medicine ,Mitral valve ,Cardiology ,Medicine ,Observational study ,In patient ,030212 general & internal medicine ,Cardiology and Cardiovascular Medicine ,business - Abstract
Percutaneous edge-to-edge mitral valve (MV) repair is a relatively new treatment option for mitral regurgitation (MR). After the feasibility and safety having been proved in low-surgical-risk patients, the use of this procedure has shifted more to the treatment of high-risk patients. With the absence of randomized controlled trials (RCT) for this particular subgroup, observational studies try to add evidence to the safety aspect of this procedure. These also provide short- and mid-term mortality figures. Several mortality predictors have been identified, which may help the optimal selection of patients who will benefit most from this technique. In this article we provide an overview of the literature about mortality and its predictors in patients treated with the percutaneous edge-to-edge device.
- Published
- 2016
31. Percutaneous Edge-to-Edge Mitral Valve Repair in High-Surgical-Risk Patients
- Author
-
Benno J. Rensing, Frank D. Eefting, Martijn C. Post, Ben J L Van den Branden, Martin J. Swaans, Jan Van der Heyden, and Wybren Jaarsma
- Subjects
medicine.medical_specialty ,Mitral regurgitation ,Mitral valve repair ,education.field_of_study ,Ejection fraction ,business.industry ,MitraClip ,medicine.medical_treatment ,Population ,medicine.disease ,Surgery ,medicine.anatomical_structure ,Heart failure ,Internal medicine ,Mitral valve ,Cardiology ,medicine ,Cardiology and Cardiovascular Medicine ,education ,business ,Percutaneous Mitral Valve Repair - Abstract
Objectives This study sought to assess the feasibility and safety of percutaneous edge-to-edge mitral valve (MV) repair in patients with an unacceptably high operative risk. Background MV repair for mitral regurgitation (MR) can be accomplished by use of a clip that approximates the free edges of the mitral leaflets. Methods All patients were declined for surgery because of a high logistic EuroSCORE (>20%) or the presence of other specific surgical risk factors. Transthoracic echocardiography was performed before and 6 months after the procedure. Differences in New York Heart Association (NYHA) functional class, quality of life (QoL) using the Minnesota questionnaire, and 6-min walk test (6-MWT) distances were reported. Results Fifty-five procedures were performed in 52 patients (69.2% male, age 73.2 ± 10.1 years, logistic EuroSCORE 27.1 ± 17.0%). In 3 patients, partial clip detachment occurred; a second clip was placed successfully. One patient experienced cardiac tamponade. Two patients developed inguinal bleeding, of whom 1 needed surgery. Six patients (11.5%) died during 6-month follow-up (5 patients as a result of progressive heart failure and 1 noncardiac death). The MR grade before repair was ≥3 in 100%; after 6 months, a reduction in MR grade to ≤2 was present in 79% of the patients. Left ventricular (LV) end-diastolic diameter, LV ejection fraction, and systolic pulmonary artery pressure improved significantly. Accompanied improvements in NYHA functional class, QoL index, 6-MWT distances, and log N-terminal pro–B-type natriuretic peptide were observed. Conclusions In a high-risk population, MR reduction can be achieved by percutaneous edge-to-edge valve repair, resulting in LV remodeling with improvement of functional capacity after 6 months.
- Published
- 2012
- Full Text
- View/download PDF
32. Percutaneous mitral valve repair using the edge-to-edge technique in a high-risk population
- Author
-
Frank D. Eefting, H. W. M. Plokker, W. Jaarsma, B. J. L. Van den Branden, J. A. S. der Van Heyden, Benno J. Rensing, Martijn C. Post, and M. J. Swaans
- Subjects
medicine.medical_specialty ,Mitral regurgitation ,Mitral valve repair ,education.field_of_study ,Percutaneous ,business.industry ,medicine.medical_treatment ,Population ,medicine.disease ,Surgery ,medicine.anatomical_structure ,Quality of life ,Mitral valve ,Internal medicine ,cardiovascular system ,Cardiology ,medicine ,Original Article ,cardiovascular diseases ,Cardiology and Cardiovascular Medicine ,education ,business ,Mitral valve regurgitation ,Percutaneous Mitral Valve Repair - Abstract
Background. Percutaneous mitral valve (MV) repair using the edge-to-edge clip technique might be an alternative for patients with significant mitral regurgitation (MR) and an unacceptably high risk for operative repair or replacement. We report the short-term safety and efficacy of this new technique in a high-risk population. Methods. All consecutive high-risk patients who underwent percutaneous MV repair with the Mitraclip® between January and August 2009 were included. All complications related to the procedure were reported. Transthoracic echocardiography for MR grading and right ventricular systolic pressure (RVSP) measurement were performed before, and at three and 30 days after the procedure. Differences in NYHA functional class and quality of life (QoL) index were reported. Results. Nine patients were enrolled (78% male, age 75.9±9.0 years, logistic EuroSCORE 33.8±9.0%). One patient developed inguinal bleeding. In one patient partial clip detachment occurred, a second clip was placed successfully. The MR grade before repair was ≥3 in 100%, one month after repair a reduction in MR grade to ≤2 was present in 78% (p=0.001). RVSP decreased from 43.9±12.1 to 31.6±11.7 mmHg (p=0.009), NYHA functional class improved from median 3 (range 3 to 4) to 2 (range 1 to 4) (p=0.04), and QoL index improved from 62.9±16.3 to 49.9±30.7 (p=0.12). Conclusion. In high-risk patients, transcatheter MV repair seems to be safe and a reduction in MR can be achieved in most patients, resulting in a short-term improvement of functional capacity and QoL. (Neth Heart J 2010;18:437–43.)
- Published
- 2010
- Full Text
- View/download PDF
33. Natural Killer Cells and CD4 + T-Cells Modulate Collateral Artery Development
- Author
-
Abbey Schepers, Paul H.A. Quax, Paul H. C. Eilers, Victor W.M. van Hinsbergh, J.H. van Bockel, M.R. de Vries, V. van Weel, René E. M. Toes, D. Eefting, L. Seghers, J. Sipkens, M.M.L. Deckers, TNO Kwaliteit van Leven, ICaR - Ischemia and repair, and Physiology
- Subjects
CD4-Positive T-Lymphocytes ,Biomedical Research ,Angiogenesis ,CD3 ,Collateral Circulation ,Neovascularization, Physiologic ,Arterial Occlusive Diseases ,Major histocompatibility complex ,Natural killer cell ,Mice ,Immune system ,vascularization ,Ischemia ,medicine ,Animals ,Mice, Knockout ,Mice, Inbred BALB C ,biology ,T lymphocyte ,biological marker ,Collateral circulation ,Hindlimb ,Femoral Artery ,Killer Cells, Natural ,Disease Models, Animal ,medicine.anatomical_structure ,Peripheral vascular disease ,Immunology ,CD3 antigen ,biology.protein ,Animal models of human disease ,Arteriogenesis ,CD4 antigen ,Cardiology and Cardiovascular Medicine - Abstract
Objective— The immune system is thought to play a crucial role in regulating collateral circulation (arteriogenesis), a vital compensatory mechanism in patients with arterial obstructive disease. Here, we studied the role of lymphocytes in a murine model of hindlimb ischemia. Methods and Results— Lymphocytes, detected with markers for NK1.1, CD3, and CD4, invaded the collateral vessel wall. Arteriogenesis was impaired in C57BL/6 mice depleted for Natural Killer (NK)-cells by anti-NK1.1 antibodies and in NK-cell–deficient transgenic mice. Arteriogenesis was, however, unaffected in Jα281-knockout mice that lack NK1.1 + Natural Killer T (NKT)-cells, indicating that NK-cells, rather than NKT-cells, are involved in arteriogenesis. Furthermore, arteriogenesis was impaired in C57BL/6 mice depleted for CD4 + T-lymphocytes by anti-CD4 antibodies, and in major histocompatibility complex (MHC)-class-II–deficient mice that more selectively lack mature peripheral CD4 + T-lymphocytes. This impairment was even more profound in anti-NK1.1-treated MHC-class-II–deficient mice that lack both NK- and CD4 + T-lymphocytes. Finally, collateral growth was severely reduced in BALB/c as compared with C57BL/6 mice, 2 strains with different bias in immune responsiveness. Conclusions— These data show that both NK-cells and CD4 + T-cells modulate arteriogenesis. Promoting lymphocyte activation may represent a promising method to treat ischemic disease.
- Published
- 2007
- Full Text
- View/download PDF
34. Unintentional sealing of the mitral valve with a second MitraClip. 'Once bitten, twice shy'
- Author
-
Martin J. Swaans, Frank D. Eefting, van der Heyden Ja, Martijn C. Post, Alipour A, and Benno J. Rensing
- Subjects
medicine.medical_specialty ,Mitral Valve Annuloplasty ,Mitral Valve Prolapse ,business.industry ,MitraClip ,Mitral Valve Insufficiency ,medicine.disease ,Surgical Instruments ,Surgery ,Echocardiography, Doppler, Color ,medicine.anatomical_structure ,Mitral valve ,Mitral valve annuloplasty ,medicine ,Mitral valve prolapse ,Humans ,Mitral Valve ,Female ,Cardiology and Cardiovascular Medicine ,business ,Aged - Published
- 2015
35. Experience with the GORE EXCLUDER iliac branch endoprosthesis for common iliac artery aneurysms
- Author
-
Steven M.M. van Sterkenburg, Jan M.M. Heyligers, Mathijs van Bladel, Hence J. Verhagen, Daniël Eefting, Marc R. van Sambeek, Clark J. Zeebregts, Michel M.P.J. Reijnen, J. Avontuur, T. Smits, M.R. van Sambeek, R.B.M. van Tongeren, H.J. Verhagen, G. Akkersdijk, D. Eefting, O.R.M. Wikkeling, C.J.J.M. Sikkink, M. van Bladel, S. Holewijn, E. Mathijssen, M.M.P.J. Reijnen, S.M.M. van Sterkenburg, J.M.M. Heyligers, T. Koëter, J. van Brussel, C.J. Zeebregts, I.F.J. Tielliu, Surgery, and Man, Biomaterials and Microbes (MBM)
- Subjects
Male ,medicine.medical_specialty ,Time Factors ,Computed Tomography Angiography ,medicine.medical_treatment ,Operative Time ,030204 cardiovascular system & hematology ,Prosthesis Design ,Medical Records ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,Blood Vessel Prosthesis Implantation ,0302 clinical medicine ,Aneurysm ,Postoperative Complications ,Blood vessel prosthesis ,medicine.artery ,EXCLUSION ,Medicine ,Humans ,Iliac Aneurysm ,Embolization ,PRESERVATION ,Vascular Patency ,Computed tomography angiography ,Aged ,Netherlands ,Retrospective Studies ,REPAIR ,medicine.diagnostic_test ,business.industry ,Endovascular Procedures ,GRAFT ,Retrospective cohort study ,Middle Aged ,medicine.disease ,EMBOLIZATION ,Common iliac artery ,Surgery ,Blood Vessel Prosthesis ,Treatment Outcome ,Cohort ,Retreatment ,Female ,Stents ,Cardiology and Cardiovascular Medicine ,business - Abstract
Objective: In this study, we analyzed the procedural success and early outcome of endovascular treatment of a multicenter cohort of patients with common iliac artery (CIA) aneurysms treated with the new GORE EXCLUDER (W. L. Gore & Associates, Flagstaff, Ariz) iliac branch endoprosthesis (IBE).Methods: A retrospective cohort analysis was performed in 13 sites in The Netherlands. Anatomic, demographic, procedural, and follow-up data were assessed from hospital records.Results: From November 2013 to December 2014, 51 CIA aneurysms were treated with an IBE in 46 patients. The median diameter of the treated aneurysm was 40.5 (range, 25.0-90.0) mm. The mean procedural time was 198 +/- 56 minutes. All but one implantation were successful; two type Ib endoleaks were noticed, resulting in a procedural success rate of 93.5%. The two type Ib endoleaks spontaneously disappeared at 30 days. There was no 30-day mortality. Ipsilateral buttock claudication was present in only two cases at 30 days and disappeared during follow-up. The incidence of reported erectile dysfunction was low and severe ischemic complications were absent. After a mean follow-up of 6 months, data on 17 treated aneurysms were available. Two showed a stable diameter, whereas 15 showed a mean decrease of 3.9 +/- 2.2 mm (P Conclusions: The use of the GORE EXCLUDER IBE device for CIA aneurysms is related to high procedural success, high patency rates, and low reintervention rates at short-term follow-up. Prospective data with longer follow-up are awaited to establish the role of the device in the treatment algorithm of CIA aneurysms.
- Published
- 2015
36. Primary Stenting of Totally Occluded Native Coronary Arteries II (PRISON II)
- Author
-
Gert Jan Laarman, Ferdinand Kiemeneij, Frank D. Eefting, Mike A.R. Bosschaert, Egbert T. Bal, E. Gijs Mast, Benno J. Rensing, Braim M. Rahel, Maarten J. Suttorp, Jur M. ten Berg, and Johannes C. Kelder
- Subjects
Male ,Bare-metal stent ,medicine.medical_specialty ,medicine.medical_treatment ,Myocardial Ischemia ,Coronary Angiography ,law.invention ,Randomized controlled trial ,Restenosis ,Risk Factors ,law ,Physiology (medical) ,Internal medicine ,Angioplasty ,medicine ,Humans ,Stent implantation ,Single-Blind Method ,cardiovascular diseases ,Aged ,Sirolimus ,business.industry ,Coronary Stenosis ,Stent ,Equipment Design ,Middle Aged ,equipment and supplies ,medicine.disease ,Anti-Bacterial Agents ,Surgery ,Coronary arteries ,surgical procedures, operative ,medicine.anatomical_structure ,Cardiology ,Female ,Stents ,Cardiology and Cardiovascular Medicine ,business ,Follow-Up Studies ,medicine.drug - Abstract
Background— Sirolimus-eluting stents markedly reduce the risk of restenosis compared with bare metal stents. However, it is not known whether there are differences in effectiveness between bare metal and sirolimus-eluting stents in patients with total coronary occlusions. Methods and Results— In a prospective, randomized, single-blind, 2-center trial, we enrolled 200 patients with total coronary occlusions: Half (n=100) were randomly assigned to receive bare metal BxVelocity stents and half (n=100) to receive sirolimus-eluting Cypher stents. The primary end point was angiographic binary in-segment restenosis rate at 6-month follow-up. Secondary end points were a composite of major adverse cardiac events, target vessel failure, binary in-stent restenosis rate, in-stent and in-segment minimal lumen diameter, percent diameter stenosis, and late luminal loss at 6-month follow-up. The sirolimus stent group showed a significantly lower in-stent binary restenosis rate of 7% compared with 36% in the bare metal stent group ( P P P Conclusions— In patients with total coronary occlusions, use of the sirolimus-eluting stents are superior to the bare metal stents with significant reduction in angiographic binary restenosis, resulting in significantly less need for target lesion and target vessel revascularization.
- Published
- 2006
- Full Text
- View/download PDF
37. Randomized Comparison Between Stenting and Off-Pump Bypass Surgery in Patients Referred for Angioplasty
- Author
-
Diederick E. Grobbee, Harry Suryapranata, Jaap R. Lahpor, Erik Buskens, Erik W.L. Jansen, Pieter R. Stella, Willem J.L. Suyker, Hendrik M. Nathoe, Peter de Jaegere, Jan C. Diephuis, Cornelius Borst, Frank D. Eefting, Diederik van Dijk, and Sjef Ernst
- Subjects
Male ,medicine.medical_specialty ,Cost-Benefit Analysis ,medicine.medical_treatment ,Myocardial Infarction ,Balloon ,Angina Pectoris ,law.invention ,Angina ,Surgical anastomosis ,Recurrence ,law ,Surveys and Questionnaires ,Physiology (medical) ,Angioplasty ,Cardiopulmonary bypass ,Humans ,Medicine ,Life Tables ,Myocardial infarction ,Coronary Artery Bypass ,Stroke ,Aged ,Netherlands ,business.industry ,Middle Aged ,medicine.disease ,Surgery ,Treatment Outcome ,Bypass surgery ,Female ,Stents ,Quality-Adjusted Life Years ,Cardiology and Cardiovascular Medicine ,business ,Angioplasty, Balloon ,Follow-Up Studies - Abstract
Background— Stenting improves cardiac outcome in comparison with balloon angioplasty. Compared with conventional surgery, off-pump bypass surgery on the beating heart without cardiopulmonary bypass may reduce morbidity, hospital stay, and costs. The purpose, therefore, was to compare cardiac outcome, quality of life, and cost-effectiveness 1 year after stenting and after off-pump surgery. Methods and Results— Patients referred for angioplasty (n=280) were randomly assigned to stenting (n=138) or off-pump bypass surgery. At 1 year, survival free from stroke, myocardial infarction, and repeat revascularization was 85.5% after stenting and 91.5% after off-pump surgery (relative risk, 0.93; 95% CI, 0.86 to 1.02). Freedom from angina was 78.3% after stenting and 87.0% after off-pump surgery ( P =0.06). Quality-adjusted lifetime was 0.82 year after stenting and 0.79 year after off-pump surgery ( P =0.09). Hospital stay after the initial procedure was 1.43 and 5.77 days, respectively ( P P Conclusions— At 1 year, stenting was more cost-effective than off-pump surgery while maintaining comparable cardiac outcome and quality of life. Stenting rather than off-pump surgery, therefore, can be recommended as a first-choice revascularization strategy in selected patients.
- Published
- 2003
- Full Text
- View/download PDF
38. TIDES-ACS Trial: comparison of titanium-nitride-oxide coated bio-active-stent to the drug (everolimus)-eluting stent in acute coronary syndrome. Study design and objectives
- Author
-
E B, Colkesen, F D, Eefting, B J, Rensing, M J, Suttorp, J M, Ten Berg, P P, Karjalainen, and J A, Van Der Heyden
- Subjects
Coronary Restenosis ,Titanium ,Research Design ,Humans ,Drug-Eluting Stents ,Stents ,Everolimus ,France ,Prospective Studies ,Acute Coronary Syndrome ,Finland ,Netherlands - Abstract
Drug-eluting stents (DES), delivering antiproliferative drugs from a durable polymer, have shown to reduce in-stent restenosis after percutaneous coronary intervention (PCI) compared to bare-metal stents (BMS). However, they have been associated with a hypersensitivity reaction, delayed healing, and incomplete endothelialization, which may contribute to an increased risk of late stent thrombosis. Consequently, a prolonged duration of dual antiplatelet therapy (DAPT) is needed, with an increased risk of bleeding complication. A number of stent technologies are being developed in an attempt to modify late thrombotic events and DAPT duration. The Optimax™ stent is such a novel, next generation bioactive stent (BAS), in which a thicker layer of titanium-nitride-oxide coating is inserted over the stent struts. The rationale of this is to obtain more efficient and rapid vascular healing at the site of the stent implantation. The aim of TIDES-ACS Trial is to compare clinical outcome in patients presenting with ACS, treated with PCI using Optimax-BAS versus Synergy™-EES. Second objective is to explore whether the Optimax™-BAS use is superior compared with Synergy™-EES use with respect of hard end points (cardiac death, myocardial infarction [MI] and major bleeding). A prospective, randomized, multicenter trial (ClinicalTrials.gov Identifier: NCT02049229), will be conducted in interventional centres in Finland (six centres), France (five centres) and Holland (two centres), including a total of 1800 patients.
- Published
- 2015
39. Endovascular Salvage of a False Aneurysm of the Posterior Tibial Artery Caused by a Stab From a Stingray
- Author
-
Hence J.M. Verhagen, Adriaan Moelker, E.J. van Helden, J. Florie, D. Eefting, Surgery, and Radiology & Nuclear Medicine
- Subjects
medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,medicine.disease ,Stab ,Posterior tibial artery ,Aneurysm ,X ray computed ,medicine.artery ,Stingray ,medicine ,Radiology, Nuclear Medicine and imaging ,Radiology ,Embolization ,Ultrasonography ,Cardiology and Cardiovascular Medicine ,business - Published
- 2015
40. Elevated high-sensitive cardiac troponin T levels are associated with low skeletal muscle mass in abdominal surgical oncology patients at risk for coronary artery disease
- Author
-
Peter G. Noordzij, Djamila Boerma, Ineke M. Dijkstra, Jeroen L.A. van Vugt, Frank D. Eefting, Jan N. M. IJzermans, Thomas L. Bollen, and Surgery
- Subjects
Male ,medicine.medical_specialty ,Cachexia ,Cardiac troponin ,Coronary Artery Disease ,High sensitive ,Cohort Studies ,Coronary artery disease ,Troponin T ,Risk Factors ,Surgical oncology ,Intensive care ,Anesthesiology ,medicine ,Humans ,Muscle Strength ,Muscle, Skeletal ,biology ,business.industry ,General surgery ,Middle Aged ,medicine.disease ,Skeletal muscle mass ,Troponin ,humanities ,Surgery ,Abdominal Neoplasms ,biology.protein ,Female ,Cardiology and Cardiovascular Medicine ,business ,Biomarkers - Abstract
a Department of Surgery, Erasmus University Medical Center, Rotterdam, The Netherlands b Department of Surgery, St Antonius Hospital, Nieuwegein, The Netherlands c Department of Clinical Chemistry, St Antonius Hospital, Nieuwegein, The Netherlands d Department of Radiology, St Antonius Hospital, Nieuwegein, The Netherlands e Department of Cardiology, St Antonius Hospital, Nieuwegein, The Netherlands f Department of Anesthesiology, Intensive Care and Pain Medicine, St Antonius Hospital, Nieuwegein, The Netherlands
- Published
- 2015
41. The Octopus Study
- Author
-
Johannes T. A. Knape, Diederick E. Grobbee, Erik Buskens, Etienne O. Robles de Medina, Hendrik M. Nathoe, Diederik van Dijk, Peter de Jaegere, Jan C. Diephuis, Johan J. Bredée, Frank D. Eefting, Cornelius Borst, Arno P. Nierich, and Erik W.L. Jansen
- Subjects
Pharmacology ,medicine.medical_specialty ,business.industry ,Cost effectiveness ,medicine.medical_treatment ,Stent ,medicine.disease ,Surgery ,law.invention ,Clinical trial ,Angina ,surgical procedures, operative ,Randomized controlled trial ,Bypass surgery ,law ,Internal medicine ,Angioplasty ,medicine ,Clinical endpoint ,Cardiology ,cardiovascular diseases ,business - Abstract
The Octopus Study consists of two multicenter randomized clinical trials in which coronary artery bypass grafting on the beating heart (off-pump CABG) using the Utrecht Octopus Method is compared to intracoronary stent implantation and conventional CABG. The primary endpoint in the comparison of off-pump CABG versus stent implantation (OctoStent Trial) is medical effectiveness (i.e., absence of reintervention and major adverse cardiac and cerebrovascular events at 1 year after treatment). The primary endpoint in the comparison of off-pump CABG versus conventional CABG (OctoPump Trial) is cerebral safety (i.e., absence of cognitive deficits and cerebrovascular events at 3 months after treatment). Secondary endpoints in both trials include presence and severity of angina, quality of life, exercise capacity, and cost-effectiveness. A total of 560 patients will be enrolled. A random sample of 210 patients will undergo repeat angiography at 1 year to assess angiographic restenosis rate and graft patency. Including 1-year follow-up, the study will last for 3 years. Control Clin Trials 2000;21:595-609
- Published
- 2000
- Full Text
- View/download PDF
42. Shrinkage of human coronary arteries is an important determinant of de novo atherosclerotic luminal stenosis: an in vivo intravascular ultrasound study
- Author
-
M A Quarles van Ufford, Pieter C. Smits, Gerard Pasterkamp, Cornelius Borst, Frank D. Eefting, and L Bos
- Subjects
medicine.medical_specialty ,animal structures ,medicine.diagnostic_test ,Interventional cardiology ,Vascular disease ,business.industry ,medicine.disease ,Pathophysiology ,Coronary arteries ,Lesion ,Stenosis ,medicine.anatomical_structure ,Internal medicine ,Intravascular ultrasound ,medicine ,Cardiology ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,business ,Artery - Abstract
Objective To assess the occurrence of arterial remodelling types and its relation with the severity of luminal stenosis in atherosclerotic coronary arteries. Patients and methods Twenty one de novo coronary lesions of 20 patients, who were scheduled for percutaneous transluminal coronary angioplasty (PTCA), were investigated with intravascular ultrasound before PTCA. Local arterial remodelling at the lesion site was studied by measuring the cross sectional area circumscribed by the external elastic lamina (EEL) relative to the reference site: (EEL area lesion/reference EEL area) × 100%. Three groups were defined. Group A: relative EEL area of less than 95% (shrinkage), group B: relative EEL area between 95% and 105% (no remodelling), group C: relative increase in EEL area of more than 105% (compensatory enlargement). Results All three types of remodelling were observed at the lesion site: group A (shrinkage) n = 8, group B (no remodelling) n = 5, group C (compensatory enlargement) n = 8. The mean (SD) relative EEL area at the lesion site in group A and C was 83(9)% and 132(30)%, respectively. In group A, 33% of the luminal area stenosis at the lesion site was caused by shrinkage of the artery. In contrast, group C showed that 87% of the plaque area did not contribute to luminal area stenosis because of compensatory arterial enlargement. Conclusions These results show that both compensatory enlargement and paradoxical shrinkage occurs in the atherosclerotic coronary artery. Next to plaque accumulation, the type of atherosclerotic remodelling is an important determinant of luminal narrowing.
- Published
- 1998
- Full Text
- View/download PDF
43. Revascularization of patients with coronary artery disease: The interventional cardiologist's perspective
- Author
-
Etienne O. Robles de Medina, Huub W.J. Meijburg, Pieter R. Stella, Peter de Jaegere, P. W. Westerhof, and Frank D. Eefting
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,medicine.medical_treatment ,MEDLINE ,Coronary Artery Disease ,Revascularization ,Coronary artery disease ,Recurrence ,Angioplasty ,Internal medicine ,medicine ,Humans ,Combined Modality Therapy ,Angioplasty, Balloon, Coronary ,Coronary Artery Bypass ,Modalities ,business.industry ,medicine.disease ,Coronary revascularization ,Clinical research ,Cardiology ,Stents ,Surgery ,Cardiology and Cardiovascular Medicine ,business - Abstract
In the majority of patients with chronic coronary artery disease, treatment is aimed at palliation or prolongation of disease-free intervals and consists of either pharmacologic therapy or coronary revascularization. As a result of continuous refinements and improvements in both surgical and catheter-based revascularization techniques, modalities, and adjunctive pharmacologic therapy, an increasing number of patients may benefit from coronary revascularization. This also engenders difficult choices for the physicians responsible for selecting the most appropriate treatment. To achieve and provide optimal patient care an open and principled discussion with all parties involved is mandatory and must be based on the integration of clinical experience and data from both basic and clinical research. The purpose of this article is to provide the interventional cardiologist's view on the treatment of patients with atherosclerotic coronary artery disease.
- Published
- 1997
- Full Text
- View/download PDF
44. Differences in mortality, risk factors, and complications after open and endovascular repair of ruptured abdominal aortic aneurysms
- Author
-
G.C.I. von Meijenfeldt, S. ten Raa, Ellen V. Rouwet, F. Bastos Gonçalves, Klaas H.J. Ultee, J.M. Hendriks, D. Eefting, Sanne E. Hoeks, Hence J.M. Verhagen, Surgery, and Anesthesiology
- Subjects
Male ,medicine.medical_specialty ,Time Factors ,Survival ,medicine.medical_treatment ,Aortic Rupture ,Abdominal aneurysm ,Logistic regression ,Endovascular aneurysm repair ,Risk Assessment ,Ruptured endovascular procedures ,Aortic aneurysm ,Postoperative Complications ,Clinical endpoint ,medicine ,Odds Ratio ,Humans ,Risk factor ,Aged ,Netherlands ,Retrospective Studies ,Medicine(all) ,Surgical repair ,business.industry ,Endovascular Procedures ,Odds ratio ,medicine.disease ,Confidence interval ,Surgery ,Blood Vessel Prosthesis ,Treatment Outcome ,Female ,Cardiology and Cardiovascular Medicine ,business ,Aortic Aneurysm, Abdominal ,Follow-Up Studies - Abstract
Objective/background: Endovascular aneurysm repair (EVAR) for ruptured abdominal aortic aneurysm (rAAA) has faced resistance owing to the marginal evidence of benefit over open surgical repair (OSR). This study aims to determine the impact of treatment modality on early mortality after rAAA, and to assess differences in postoperative complications and long-term survival. Methods: Patients treated between January 2000 and June 2013 were identified. The primary endpoint was early mortality. Secondary endpoints were postoperative complications and long-term survival. Independent risk factors for early mortality were calculated using multivariate logistic regression. Survival estimates were obtained by means of Kaplan-Meier curves. Results: Two hundred and twenty-one patients were treated (age 72 +/- 8 years, 90% male), 83 (38%) by EVAR and 138 (62%) by OSR. There were no differences between groups at the time of admission. Early mortality was significantly lower for EVAR compared with OSR (odds ratio [OR]: 0.45, 95% confidence interval [Cl]: 0.21-0.97). Similarly, EVAR was associated with a threefold risk reduction in major complications (OR: 0.33, 95%Cl: 0.15-0.71). Hemoglobin level
- Published
- 2013
45. Complications during percutaneous edge-to-edge mitral valve repair
- Author
-
J.A.S. Van der Heyden, M. J. Swaans, Frank D. Eefting, A.L.M. Bakker, Martijn C. Post, and Benno J. Rensing
- Subjects
medicine.medical_specialty ,Mitral regurgitation ,Mitral valve repair ,Percutaneous ,Evidence-Based Medicine ,Mitral Valve Annuloplasty ,business.industry ,medicine.medical_treatment ,MitraClip ,Treatment outcome ,Coronary Sinus ,Mitral Valve Insufficiency ,Surgical risk ,Surgery ,Postoperative Complications ,Treatment Outcome ,medicine ,Humans ,In patient ,Radiology ,Cardiology and Cardiovascular Medicine ,business - Abstract
Transcatheter edge-to-edge mitral valve repair is an approach for treating mitral regurgitation, which is an alternative for surgery in patients with a high surgical risk. Although the safety and efficacy of the technique have been demonstrated, it is still associated with potentially life-threatening complications. The aim of this paper is to discuss the nature, management, and prevention of the most important procedural complications associated with this procedure.
- Published
- 2013
46. Percutaneous edge-to-edge mitral valve repair in high-surgical-risk patients: do we hit the target?
- Author
-
Ben J L, Van den Branden, Martin J, Swaans, Martijn C, Post, Benno J W M, Rensing, Frank D, Eefting, Wybren, Jaarsma, and Jan A S, Van der Heyden
- Subjects
Heart Valve Prosthesis Implantation ,Male ,Heart Valve Diseases ,Stroke Volume ,Prognosis ,Risk Assessment ,Severity of Illness Index ,Ventricular Function, Left ,Catheterization ,Echocardiography ,Surveys and Questionnaires ,Exercise Test ,Quality of Life ,Health Status Indicators ,Humans ,Mitral Valve ,Female ,Aged - Abstract
This study sought to assess the feasibility and safety of percutaneous edge-to-edge mitral valve (MV) repair in patients with an unacceptably high operative risk.MV repair for mitral regurgitation (MR) can be accomplished by use of a clip that approximates the free edges of the mitral leaflets.All patients were declined for surgery because of a high logistic EuroSCORE (20%) or the presence of other specific surgical risk factors. Transthoracic echocardiography was performed before and 6 months after the procedure. Differences in New York Heart Association (NYHA) functional class, quality of life (QoL) using the Minnesota questionnaire, and 6-min walk test (6-MWT) distances were reported.Fifty-five procedures were performed in 52 patients (69.2% male, age 73.2 ± 10.1 years, logistic EuroSCORE 27.1 ± 17.0%). In 3 patients, partial clip detachment occurred; a second clip was placed successfully. One patient experienced cardiac tamponade. Two patients developed inguinal bleeding, of whom 1 needed surgery. Six patients (11.5%) died during 6-month follow-up (5 patients as a result of progressive heart failure and 1 noncardiac death). The MR grade before repair was ≥3 in 100%; after 6 months, a reduction in MR grade to ≤2 was present in 79% of the patients. Left ventricular (LV) end-diastolic diameter, LV ejection fraction, and systolic pulmonary artery pressure improved significantly. Accompanied improvements in NYHA functional class, QoL index, 6-MWT distances, and log N-terminal pro-B-type natriuretic peptide were observed.In a high-risk population, MR reduction can be achieved by percutaneous edge-to-edge valve repair, resulting in LV remodeling with improvement of functional capacity after 6 months.
- Published
- 2011
47. Arterial occlusion after repetitive angio-seal device closure
- Author
-
Aryan Vink, Marguerite E. I. Schipper, Maarten-Jan Suttorp, Frank D. Eefting, Paul F. Liqui Lung, and Theo van den Broek
- Subjects
Male ,medicine.medical_specialty ,Closure (topology) ,Arterial Occlusive Diseases ,Femoral artery ,Endarterectomy ,Punctures ,Internal medicine ,medicine.artery ,medicine ,Angio seal ,Humans ,Vascular closure device ,Aged ,business.industry ,Hemostatic Techniques ,Angiography ,General Medicine ,medicine.disease ,Arterial occlusion ,Surgery ,Femoral Artery ,Stenosis ,Cardiology ,Cardiology and Cardiovascular Medicine ,business ,Tomography, X-Ray Computed - Published
- 2007
48. Anti-MCP-1 gene therapy inhibits vascular smooth muscle cells proliferation and attenuates vein graft thickening both in vitro and in vivo
- Author
-
D. Eefting, M.R. de Vries, Jos M. Grimbergen, Peter I. Bonta, Abbey Schepers, J.H. van Bockel, Kensuke Egashira, Paul H.A. Quax, V. van Weel, C. J. M. De Vries, Pulmonology, Amsterdam Cardiovascular Sciences, Medical Biochemistry, and TNO Kwaliteit van Leven
- Subjects
Male ,Chemokine ,Pathology ,Vein graft disease ,Intimal hyperplasia ,Vascular smooth muscle ,Biomedical Research ,Mouse ,Monocyte chemotactic protein 1 ,Artery intima proliferation ,Monocyte ,Animal tissue ,Muscle, Smooth, Vascular ,In vivo study ,Mice ,Chemokine receptor CCR2 ,Receptor ,Cell proliferation ,Cells, Cultured ,Chemokine CCL2 ,Sequence Deletion ,biology ,Anatomy ,Saphenous vein ,Gene Therapy ,Carotid Arteries ,Smooth muscle cells ,cardiovascular system ,Receptors, Chemokine ,Apolipoprotein E ,Graft failure ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,Human ,Neointima ,medicine.medical_specialty ,Receptors, CCR2 ,Hypercholesterolemia ,Myocytes, Smooth Muscle ,Inflammation ,CCL2 ,Organ Culture Techniques ,medicine ,Animals ,Humans ,Animal model ,Saphenous Vein ,Animal experiment ,Amino Acid Sequence ,Human tissue ,Biology ,Cell Proliferation ,business.industry ,In vitro study ,Genetic Therapy ,medicine.disease ,Atherosclerosis ,Nonhuman ,Vein graft ,Mice, Inbred C57BL ,Human cell ,biology.protein ,Protein expression ,business ,Tunica Intima ,Controlled study ,Carotid artery ,MCP-1 - Abstract
Objective— Because late vein graft failure is caused by intimal hyperplasia (IH) and accelerated atherosclerosis, and these processes are thought to be inflammation driven, influx of monocytes is one of the first phenomena seen in IH, we would like to provide direct evidence for a role of the MCP-1 pathway in the development of vein graft disease. Methods and Results— MCP-1 expression is demonstrated in various stages of vein graft disease in a murine model in which venous interpositions are placed in the carotid arteries of hypercholesterolemic ApoE3Leiden mice and in cultured human saphenous vein (HSV) segments in which IH occurs. The functional involvement of MCP-1 in vein graft remodeling is demonstrated by blocking the MCP-1 receptor CCR-2 using 7ND-MCP-1. 7ND-MCP1 gene transfer resulted in 51% reduction in IH in the mouse model, when compared with controls. In HSV cultures neointima formation was inhibited by 53%. In addition, we demonstrate a direct inhibitory effect of 7ND-MCP-1 on the proliferation of smooth muscle cell (SMC) in HSV cultures and in SMC cell cultures. Conclusion— These data, for the first time, prove that MCP-1 has a pivotal role in vein graft thickening due to intimal hyperplasia and accelerated atherosclerosis.
- Published
- 2006
49. Angiographic findings in monozygotic twins with coronary artery disease
- Author
-
Frank D. Eefting, Pieter R. Stella, Hendrik M. Nathoe, and Peter P.Th. de Jaegere
- Subjects
Adult ,Male ,medicine.medical_specialty ,medicine.medical_treatment ,Concordance ,Monozygotic twin ,Coronary Disease ,Coronary Angiography ,Coronary artery disease ,Angina ,Coronary artery bypass surgery ,medicine.artery ,Angioplasty ,Internal medicine ,medicine ,Diseases in Twins ,Humans ,business.industry ,Twins, Monozygotic ,Middle Aged ,medicine.disease ,Coronary arteries ,medicine.anatomical_structure ,Right coronary artery ,Cardiology ,Female ,Cardiology and Cardiovascular Medicine ,business - Abstract
B genetic and environmental factors are involved in the development of coronary artery disease (CAD). The degree of contribution of each individual risk factor on CAD is unknown. The influence of genetics in the development of CAD could be clarified by investigation of twins. A large cohort of twins with CAD had a significantly higher concordance of coronary heart death in monozygotic twins than dizygotic twins. This effect declined with age. These observations underscore the genetic influence in the development of CAD. Little is known about the angiographic expression of CAD in twins. To address this issue, we report findings of 2 monozygotic twin pairs with CAD and a systematic review of previous publications on this topic. • • • A search of systematic literature in the electronic database “Medline” via “Pubmed” was performed. With the search string “coronary disease” [MESH] and twin, 191 publications were retrieved. Further selections were made by applying the inclusion criteria: monozygotic twins with CAD, performance of coronary angiography, and case reports. The exclusion criterion was concomitant major congenital heart disease. By reading abstracts 20 publications were selected. Nine of these 20 publications were excluded by reading entire papers, because of (1) no performance of angiography, (2) no inclusion of monozygotic twins; and (3) concomitant major congenital heart disease. One additional publication was found by cross-reference search. Finally, 12 publications were suitable for the present review. A 1-page standard form was developed to process the selected publications systematically. This form was the basis for Table 1. Demographic, clinical, and angiographic characteristics of the retrieved case reports, together with the present twin pairs, were analyzed according to the following definitions: concordant coronary anatomy was defined as similar dominance or balance of the coronary system (according to Baim and Grossmann) between respective members of twin pairs. The extent of CAD was defined as (1) 1-, 2-, or 3-vessel disease according to significant lesions in 1 to 3 major epicardial coronary arteries; (2) diameter stenosis of the coronary artery 50%; (3) significant stenosis of the left main coronary artery reported separately as left main disease; (4) concordant coronary lesion defined as location of a coronary lesion in the same segment (American College of Cardiology/American Heart Association classification) in respective members of twin pairs; (5) 1 lesion in the same coronary segment, considered as 1 lesion; and (6) main lesion of major coronary arteries also including the origin of side branches, considered as 1 stenosis of only the major artery. A Pearson correlation coefficient was applied to correlate continuous data among twin members, and a chi-square test was performed for dichotomous data. Twin 1.1: A 58-year-old women with Canadian Cardiovascular Society classification 3 angina was referred to our hospital for coronary angioplasty. Ischemia was documented during the exercise test. Angioplasty of a type B2 lesion in segment 2 (American College of Cardiology/American Heart Association classification) of the right coronary artery was performed with implantation of a 3.0 20 mm stent (Figure 1). Twin 1.2: Six months later the monozygotic twin sister of twin 1.1 also underwent coronary angioplasty because of class 3 angina and ischemia on exercise testing. Angioplasty of a type B1 lesion of segment 2 of the right coronary artery was performed with implantation of a 3.5 13 mm stent. The left coronary arteries of both twins were normal (Figure 2). Twin 2.1: A 39-year-old patient was admitted to our hospital with class 4 angina. He had 3-vessel disease on the coronary angiogram (type B1 lesion in segment 2, type A lesion in segment 7, type B2 lesion in segment 11, and type B1 lesion in segment 12). Coronary artery bypass surgery was performed (Figure 3). Twin 2.2: A 34-year-old male patient, monozygotic twin brother of twin 2.1, was admitted to our hospital because of an acute inferior wall myocardial infarction and was treated with fibrinolysis. Because of postinfarction angina pectoris, coronary angiography was performed and 2-vessel coronary disease was found (type B1 lesion in segment 2 and type B2 lesion in segment 8, Figure 4). He also underwent a coronary artery bypass surgery. Twelve publications composed of 16 monozygotic twin pairs with angiographic assessment of CAD were found. Together with the 2 twin pairs of the present study, data of 18 twin pairs with documented CAD are listed in Table 1. Most patients were men (13 of 18). The age at which twins experienced their first coronary event was 42 12 years (mean SD), with From the Heart Lung Center Utrecht, Department of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands. Dr. Stella’s address is: Department of Cardiology, University Medical Center Utrecht, Room E01-207, PO Box 85500, 508 GA Utrecht, The Netherlands. E-mail: pstella@hli.azu.nl. Manuscript received September 25, 2001; revised manuscript received and accepted January 4, 2002.
- Published
- 2002
50. The Octopus Study: rationale and design of two randomized trials on medical effectiveness, safety, and cost-effectiveness of bypass surgery on the beating heart
- Author
-
D, van Dijk, A P, Nierich, F D, Eefting, E, Buskens, H M, Nathoe, E W, Jansen, C, Borst, J T, Knape, J J, Bredée, E O, Robles de Medina, D E, Grobbee, J C, Diephuis, and P P, de Jaegere
- Subjects
Risk ,Stroke ,Cardiopulmonary Bypass ,Research Design ,Cost-Benefit Analysis ,Quality of Life ,Humans ,Multicenter Studies as Topic ,Stents ,Angioplasty, Balloon, Coronary ,Coronary Artery Bypass ,Randomized Controlled Trials as Topic - Abstract
The Octopus Study consists of two multicenter randomized clinical trials in which coronary artery bypass grafting on the beating heart (off-pump CABG) using the Utrecht Octopus Method is compared to intracoronary stent implantation and conventional CABG. The primary endpoint in the comparison of off-pump CABG versus stent implantation (OctoStent Trial) is medical effectiveness (i.e., absence of reintervention and major adverse cardiac and cerebrovascular events at 1 year after treatment). The primary endpoint in the comparison of off-pump CABG versus conventional CABG (OctoPump Trial) is cerebral safety (i.e., absence of cognitive deficits and cerebrovascular events at 3 months after treatment). Secondary endpoints in both trials include presence and severity of angina, quality of life, exercise capacity, and cost-effectiveness. A total of 560 patients will be enrolled. A random sample of 210 patients will undergo repeat angiography at 1 year to assess angiographic restenosis rate and graft patency. Including 1-year follow-up, the study will last for 3 years. Control Clin Trials 2000;21:595-609
- Published
- 2001
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.